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The study of the dynamic movements of membrane bound proteins is typically 
achieved through an exogenously applied fluorescent tag or genetic modification of a 
receptor of interest to spatiotemporally monitor protein location. Techniques often used 
for labeling proteins include overexpression of a fluorescent protein such as GFP fused to 
a target protein or the application of antibodies. These methods benefit from superb 
specificity towards a receptor of interest, but may impose unforeseen consequences when 
studying natural protein movements. Thus, it is advantageous to development small, 
modular probes that would allow for visualization of endogenous membrane bound 
receptors in a minimally perturbed state. 
 Several strategies employing photochemical small molecules were pursued to 
label important neuronal receptor targets on live cells. One method, photoaffinity 
labeling, requires a highly specific ligand outfitted with a UV photoreactive group and an 
orthogonal handle to covalently bind the ligand to the receptor for experimental analysis 





study sigma receptors, which are believed to be involved in several neurodegenerative 
disorders and cancer pathologies.  
 Another method is fluorescently tethered small molecule ligands that utilize a 
pharmacophore covalently bound to a fluorophore for specificity and subsequent 
visualization of a receptor of interest. We have designed small, minimally-perturbing 
modular probes that enable labeling and subcellular visualization of endogenous 
receptors on live cells. This technology allows for silent labeling of a receptor of interest, 
which allows for the receptor to be tagged with a fluorescent moiety in a non-ligated and 
thus active state. Using these probes we labeled the presynaptic dopamine and serotonin 
transporters and NMDA receptors on live cells. 
  Finally, we have developed a method for facile alkylation of biological substrates 
utilizing a small, photoactivatable, electrophilc moiety that is compatible with aqueous 
buffer. We demonstrated that the molecule is reactive only in the presence of UV light, 
which gives the user temporal control over the alkylation of a nucleophile.    
 In sum, these small molecule probes will provide chemical biologists novel tools 
for labeling membrane-bound receptors to visualize their location and trafficking, which 
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GENERAL LABELING STRATEGIES 
1.1 Introduction 
The use of fluorescent molecules has revolutionized the way we can observe 
proteins, receptors, and ion channels in and on cells. These molecules have allowed for 
the study of several membrane bound proteins that can give insight into not only the 
structure of the protein, but function as well. Techniques that are widely used to label 
membrane bound proteins include overexpression of a fluorescent protein fused to a 
target protein or the application of antibodies
1
. Overexpression of a fluorescent protein 
generally relies on a gene construct being introduced to a target cell that encodes the gene 
of interest with the fusion protein. In addition, hybrid chemical/genetic strategies such as 
the tetracysteine FlAsH/ReAsH or the tetraserine RhoBo systems have also been 
developed
2,3
. Enzyme catalyzed processes are also utilized for selective chemical 






, and  
phosphopantetheinyl transferases
7
. Although these systems benefit from the superior 
specificity that is built into the system, overexpression of some fluorescent proteins are 
known to cause oligomerize under certain conditions
8
. In addition, overexpression of 
tagged monomeric subunits of heteromultimeric proteins have been shown to bias 
receptor subtype composition and function, which will make it difficult to study receptors 
in their natural state
9
. 
Another widely used method for labeling native receptors is the application of 
antibodies. This technique utilizes fairly large proteins to label and track the movement of 





provides high specificity for a target of interest due to the evolved nature of their binding. 
Unfortunately, due to the large size of the antibody coupled with the addition of a 
fluorescently labeled secondary antibody, this technique may impose unforeseen 
consequences on the natural movement of a receptor on the surface of a cell. This factor 
is especially significant when studying neuronal receptors that are moving in and out of a 
synapse, which is a distance that is not much larger than the antibody-receptor complex
10
. 
Ideally, a labeling strategy should not only be selective towards the receptor of 
interest, but also be small to be minimally perturbing to the native system. The strategy 
should be modular so it can be easily adapted for numerous uses and targets. In addition, 
if the method is also silent, one would be able to visualize the receptor in a non-ligated 
and thus non-perturbed state. Towards these ends, new small molecule probes were 
designed and synthesized for visualization of various neuronal receptors on live cells. 
They were derived from carefully chosen high affinity ligands from the literature to 
ensure selective labeling of the receptors of interest. 
As general background for this work, two methods of small molecule labeling 
will be discussed as alternatives to genetic modification or antibody labeling approaches. 
First, there will be a brief description of design strategies for photoaffinity labeling, 
which utilizes a ligand outfitted with a photoreactive group and orthogonal handle. Next, 
the three key features for fluorescently tethered ligands will be discussed: 
pharmacophore, linker, and fluorescent reporter.  Finally, the development of 
multifunctional probes will be introduced, focusing on a method for silently labeling 





1.2 Small Molecule Labeling 
Fluorescently labeled small molecule ligands have become powerful tools that can 
be utilized to study proteins on living cells. These probes generally consist of a high 
affinity ligand covalently modified in some fashion to a fluorescent reporter for binding 
and visualization of a receptor of interest, respectively
11,12
. There are two key advantages 
that are provided by the utilization of small molecules for imaging neuronal targets. First 
one must consider the minute size of a typical organic dye in comparison to the 
previously mentioned genetic and antibody techniques. Organic fluorophores generally 
consist of multiple conjugated and/or aromatic ring structures that are much smaller than 
proteins or quantum dots. Fluorescent proteins are generally in the range of 30 kDa and 4 
nm on their longest axis whereas quantum dots can be in the 15-50 nm diameter range
8
. 
In these cases, the fluorescent label could be similar in size to the receptors of interest, 
thereby increasing the likelihood of disruption to normal trafficking.  Second, small 
molecule probes can be applied to native systems that have not been genetically altered. 
As stated earlier, genetic modification with a fluorescent protein can lead to receptor 
subtype biasing as well as oligomerization, which can lead to unforeseen changes in 
receptor trafficking. By applying small molecule probes to native receptors it increases 
the likelihood of viewing natural movement of the protein. The combination of the 
diminutive size of organic fluorophores coupled with recent advances in imaging 
techniques makes for an unprecedented confluence that allows us to study neuronal 
receptor dynamics in detail that was not possible just a few years ago
13
. Two small 
molecule techniques that will be discussed in the following chapters to label neuronal 





1.2.1 Photoaffinity Labeling 
Photoaffinity labeling (PAL), a technique that was developed more than five 
decades ago
14
, is a valuable small molecule tool that can be used to study the interactions 
of ligands with their target proteins. PAL utilizes a ligand possessing a UV-photoreactive 
group that can be incubated with a receptor of interest to form a noncovalently bound 
ligand-receptor complex. Following binding, UV irradiation triggers the photoreactive 
group to produce a highly reactive intermediate that will form a covalent link between the 
ligand and the receptor at the binding site (Figure 1.1). In addition, photoaffinity labels 
typically contain orthogonal groups to facilitate the detection and identification of the 
photolabeled biomolecules. When designing photoaffinity ligands, it is important to 
establish that the incorporated photoreactive group does not significantly alter the binding 
affinity of the ligand towards the receptor when compared with the parent compound. 
The formation of a covalent ligand-receptor complex aids the study of the receptor 
because it allows for the use of more rigorous and harsher analysis tools such as SDS-









Figure 1.1. Cartoon depiction of PAL. The ligand will give specificity towards the 
receptor of interest, which will put the photoreactive group in close proximity to the 
receptor. Following irradiation with UV light the photoreactive group will create a 
covalent bond with the receptor that can then be tagged utilizing the alkyne handle. The 
tag can facilitate visualization of the receptor or affinity purification that will allow for 
subsequent mass spectroscopy studies. 
 
The choice of photoreactive group used to covalently link the ligand and receptor 
is of critical design importance for labeling experiments. In most cases, the photolabeling 
compound is a derivatized receptor agonist or antagonist. The photoreactive group is 
usually synthetically inserted into the ligand of interest, however, some ligands may 
contain moieties that are capable of intrinsic photoactivation such as sulfides, enones, 
dienones, and halogenated compounds
16
. The photoreactive group should demonstrate 
several of the following characteristics in order to successful label a receptor of interest. 
First, the molecule chosen should be as small as possible to minimize any steric 
interactions that would impact ligand-receptor binding affinity. Ideally, once a probe is 
chosen, control experiments should be performed to ensure that the binding affinity of the 







.  Second, the half life of the photoactivated species should be short 
enough to encourage covalent linkage between the photoaffinity ligand and receptor 
before disassociation can occur. At the same time, the excited state of the molecule 
should last long enough for the photoreactive group to remain in close contact with the 
binding site so that the labeling efficiency is high.  Lastly, the photoreactive group should 
be capable of attacking both C-H and nucleophilic X-H bonds at an activation 
wavelength that would not damage proteins
15
. 
The most commonly used photoreactive groups for PAL studies are aryl azides, 
diazirines, and benzophenone based compounds (Figure 1.2)
17,18
. The aryl azide and 
diazirines moieties are precursors of nitrene and carbene groups, while benzophenone 
based probes rely on the reactivity of aryl ketones
19
. Nitrene and carbene intermediates 
are capable of rapidly reacting with double bonds or heteroatoms in addition to 
chemically ‘inert’ aliphatic C-H bonds
20
. Benzophenones generate reactive triplet 
carbonyl states upon irradiation with 350 nm light. They are generally more stable to 
solvent than other photoreactive groups, however, they require long irradiation periods 
that bears a risk for non-specific labeling
21
. The broad reactivity of these photoreactive 
moieties allow for almost all functional groups found in biomolecules to be available for 
forming covalent bonds. 
 






 As mentioned previously, photoaffinity labels often contain an orthogonal handle 
in addition to the photoreactive group to facilitate further study of the ligand-receptor 
complex. Most often these groups are biotin, radioactive isotopes, fluorescent groups, and 
alkyne moieties, which all help with the detection of a receptor in a complex matrix such 
as cell lystate
15
. For example, after cross-linking a photoaffinity label to a receptor of 
interest, an alkyne handle can be reacted with biotin-azide in a highly specific 1,3-dipolar 
cycloaddition reaction. The biotin will allow for affinity purification of the labeled 
receptor, which can be followed by trypsin digest and analysis by mass spectroscopy. The 
coupling of receptor labeling with mass spectroscopy allows for information on receptor-
ligand interactions to be obtained on several levels. For instance, these techniques can be 
used to screen for the target of a particular ligand or drug candidate, find information of 
the binding region through mass spectroscopy based sequencing, or identify specific 
amino acids involved in interaction with the ligand in the binding pocket
15
. The results 
obtained at this level will be useful in developing 3D models of the ligand-receptor 
complex, and therefore become a key component in effective structure based drug design. 
1.2.2 Fluorescently tethered ligands 
 The first fluorescent labeling with a selective small molecule ligand that targeted 
the β-adrenergic receptors was reported in 1976
22
. In this work, the authors conjugated 
the antagonist propranolol to a 9-aminoacridine fluorophore, which was then used to 
label β-receptors in rat cerebellum. Since then, many more have followed, displaying that 
receptor selective fluorescent ligands are powerful tools for studying receptor physiology 
or pathophysiology on the cellular or subcellular level
23
. Fluorescent small molecule 





replace radioligands due their expense, health risks, and disposal issues
23
. Fluorescent 
molecules not only solve many of these drawbacks, but also can provide other 
advantages. Fluorescent molecules allow for real-time visualization and tracking of the 
labeled receptor, which can provide information on dynamic changes like agonist-
stimulated receptor internalization, endocytosis, and receptor recycling
24
.  
There are several factors that must be considered when designing small molecule 
fluorescent ligands (Figure 1.3). The ligand and fluorophore must work together to not 
only bind to the proper target of interest, but also provide high efficiency fluorescence for 
visualization of the receptor. The pharmacophore should be potent and selective, as well 
as allow for chemical functionalization via coupling to a linker and fluorophore. If there 
are no easily available sites for modification, functionalization can be built into the 
system by chemical means. In one such instance, Bai et al. described the synthesis of a 
fluorescent molecule for the study of the cannabinoid receptor, CB2
25
. The 
pharmacophore chosen, SR144528, didn’t easily allow for a fluorophore to be conjugated 
through a linker. However, the parent compound was modified to contain an alkyl 
bromide group, which was followed by a substitution reaction with an amine linker for 
conjugation to a near-infrared dye
25
. Another factor to consider is the location of the 
fluorophore on the ligand chosen, which may alter affinity towards the receptor of 
interest. For example, Yates et al. were interested in studying the CB2 receptor by 
conjugating the fluorescent dye nitrobenzodiazole (NBD) directly to a CB2 agonist. The 
new fluorescent probe lost extensive binding affinity towards CB2, which was ultimately 








Figure 1.3. Cartoon representation of an ideal ligand/fluorophore pairing. 
Representation of a ligand that is appropriately decorated with a tethered fluorophore 
bound to the protein. In this specific case, the ligand is able to bind properly in the 
binding pocket due to the optimized length of the tether and fluorophore positioning.  The 
upper right box shows two probes that will not work for this protein. One probe is 
functionalized with the tether in the wrong spot on the pharmacophore that would not 
allow the pharmacophore to bind properly with the protein. The other has a tether to the 
fluorophore that is too short, which would put the fluorophore too close to the protein and 
not allow the pharmacophore to enter the binding pocket. 
 
The choice of the size and composition of the linker between the pharmacophore 
and fluorescent dye also plays an important role in potency as well as where the 
fluorophore will be positioned in proximity to the receptor
27
. The ideal spacer length 
should be derived from an optimization process taking into account the specific 
pharmacophore, fluorophore, and the environment in which they will be applied. To date, 
only a few studies have reported systematic evaluation of spacer length for the 
fluorescent probe being studied
28,29
. In general, longer linkers have been used for bulky 





steric interactions with the target protein
25,30
. Another important consideration is that 
lipophilicity can play a factor in contributing to non-specific binding of some reported 
probes
31,29 ,32




Finally, the chosen fluorophore should have high fluorescence intensity, be 
photostable, and have the proper excitation and emission profile for system being 
studied
23
. Fluorophores that are often used for fluorescent imaging include fluorescein, 
coumarin, dansyl, cyanine, rhodamine derivatives, and NBD as mentioned previously. 
More recently, there have also been several reported BODIPY based probes as well
23
. 
Fluorophores with excitation or emission wavelengths in the region of the visible light 
spectrum where cells exhibit high levels of autofluorescence and light scattering should 
be avoided to improve signal to noise ratio
34
. Care must also be taken to avoid any other 
fluorescent markers that are already present in the cells of interest such as a GFP-tagged 
protein. 
Fluorescently tethered ligands can provide a multitude of valuable information 
about a receptor of interest. Tight binding of these fluorescent small molecules can give 
information regarding the mechanism of ligand binding, the fate of the receptor after 
binding events such as internalization, and the structure of the binding pocket
11,35,36
. 
Small molecule fluorophores have allowed for the development of pharmacological 
assays on the single cell level through their combination with fluorescent techniques such 
as fluorescence recovery after photobleaching, fluorescence correlation spectroscopy, and 
fluorescence resonance energy transfer microscopy
37
. Environment-sensitive 





employed to study the surrounding environments of these receptors. These molecules 
exhibit low quantum yields in aqueous solution, but become much more fluorescent when 
bound to a hydrophobic site in proteins or membranes
28,38,39
. Probes that contain red to 
near infrared emitting fluorophores have potential for use in vivo studies due to their 
longer excitation wavelengths, which not only allow for deeper penetration in living 
tissues, but are also less damaging to the cellular environment. In addition, these 
fluorophores allow for less light scattering compared to dyes with shorter excitation 
wavelengths, which reduces background noise and improves sensitivity
34
.     
1.2.3 Multifunctional small molecule probes 
As previously discussed, small molecule fluorescent probes are powerful tools 
that have been used to label and track membrane bound receptors. However, there are 
some drawbacks to the current technology that limit their use. Due to the reliance on 
maintained receptor occupancy by these probes during imaging, one would only be able 
to observe receptors in a ligand bound, and thus perturbed, state. It has been shown that 
persistence of receptor activation by an agonist can cause conformational changes of 
several receptor types and also induce clathrin-mediated endocytosis or differential 
trafficking patterns
40,41,42
. Ideally, a molecular probe should not only be highly specific 
for a target of interest and contain a high contrast agent easily detected from the 
background fluorescence, it should also be traceless with regard to the ligand binding site 
to minimize the difference between the labeled and unlabeled state. Previous work in our 
lab was toward the development of a small, minimally-perturbing fluorescent probe that 
enabled labeling and subcellular visualization of endogenous glutamatergic α-amino-3-







. Nanoprobe 1 much like the small molecule probes discussed earlier, utilizes a 
ligand for specificity towards AMPA receptors and a Cy3 dye for visualization (Figure 
1.4).  
 
Figure 1.4. Structure of Nanoprobe 1. 
  
This probe exceeds the previous discussed technology because there are two key 
additions to the molecule that allow for the permanent labeling of the receptor, as well as 
a method for excising the ligand: a promiscuous acrylamide electrophile for crosslinking 
to the receptor of interest and a photolabile nitroindoline core that facilitates the removal 
of the ligand following irradiation with 365 nm light (Figure 1.5)
43
. The combination of 
these functional groups allow for a receptor to be tagged with a fluorescent moiety in a 
non-ligated and thus active state. This technology has allowed us to visualize and track 









Figure 1.5. Cartoon depiction of nanoprobe labeling. Binding of the ligand (purple 
rectangle) to the receptor of interest brings the acrylamide electrophile (green square) in 
close proximity to a nucleophile to covalently bond the probe to the receptor. Following 
irradiation with UV light to cleave the photolabile core (purple square), the ligand is 
removed from the binding site to leave behind a fluorophore (red square) covalently bond 
to the receptor. 
 
The background described above is applied to several of the following chapters, 
which describes the work done towards designing and synthesizing small molecule 
fluorescent tools for labeling endogenous proteins. Some of these probes were used to 
directly to label neuronal receptors on live cells, the results of which are described in 
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PHOTOAFFINITY LIGANDS FOR SIGMA RECEPTORS 
2.1 Introduction 
Sigma receptors were initially classified as a subclass of opioid receptors 
proposed by Martin et al
1
. Further studies, however, showed that the sigma binding sites 
were a distinct class of receptors located in both the central nervous system  (CNS) as 
well as a variety of tissues and organs. These studies demonstrated that there were at least 
two types of sigma receptors; sigma 1 and sigma 2, which were distinguished based on 







Both receptors bind pentazocine whereas only the sigma 2 receptor binds DTG
2
.  
Sigma 1 receptors reside at the endoplasmic reticulum (ER)–mitochondrion 
interface called the mitochondrion-associated ER membrane (MAM). At the MAM, the 
sigma 1 receptor regulates the stability of inositol 1,4,5-trisphosphate receptors, which 
ensures proper Ca
2+
 signaling between the ER and mitochondrion
3
. These receptors also 
regulate of the level of reactive oxygen species to control the dendritic spine arborization 
in neurons. The sigma 1 receptor consists of 223 amino acids and has been cloned from 
several mammalian species, which has been found to be 90% identical and have 95% 
similar amino acid sequences across species
3
. Although the sequence of sigma 1 has been 
characterized, the physiological role it plays remains largely elusive. There is increasing 
evidence that links the sigma 1 receptor to neuroprotective/neuroregulatory functions as 
well as to CNS pathologies such as schizophrenia, depression, and Alzheimer’s and 
Parkinson’s diseases
4,5,6





lateral sclerosis (ALS) is caused by a mutation in the gene encoding the sigma 1 
receptor
7
.   
The sigma 2 receptor, unlike sigma 1, has yet to be cloned and its exact 
distribution is still not clear. Despite this, the sigma 2 receptor has been validated as a 
biomarker for tumor cell proliferation and as a target for chemotherapy. Sigma 2 
receptors are expressed in high density of nearly all human and rodent tumor cell lines
8
. 
The density of these receptors in proliferating mouse mammary adenocarcinoma cells 
was found to be about ten-fold higher than that in the corresponding quiescent tumor cells 
both in vitro and in vivo
9,10
. Therefore, the sigma 2 receptor has become an attractive 
target for the development of small molecule probes for diagnostic imaging of solid 
tumors and as a druggable site for cancer treatment
11,12,13
. 
At the start of our work on this project, it was clear that both sigma receptors were 
interesting targets due to their involvement in various neurodegenerative diseases and the 
lack of information concerning the identity of sigma 2. We sought to synthesize small 
molecule probes that would allow for labeling and subsequent visualization of these 
receptors in live cells. One method of small molecule labeling is the use of photoaffinity 
ligands, which was described in chapter 1. Briefly, photoaffinity labeling utilizes a highly 
specific ligand outfitted with a UV photoreactive group and an orthogonal handle. 
Following binding to the receptor, UV irradiation produces a reactive intermediate that 
covalently links the ligand to the receptor. The orthogonal handle can then be utilized for 






 Our first step was to identify various ligands that were potent towards the sigma 
receptor and were also amendable for modification with a photoreactive group. The main 
goal of the project was to synthesis photoaffinity ligands that could be used to label 
sigma 1 receptors on live cells. We chose the sigma 1 receptor because it was a more 
validated target, which would make it easier to determine that the ligand was reacting 
with the right receptor. However, because the pharmacology of the sigma receptors tends 
to overlap in several ways, we anticipated that the probe may also provide information on 
the identity of sigma 2.   
2.1.1 Probe design 
 One of the first pharmacological models used to understand structural 
requirements for ligand binding to sigma receptors was developed by Glennon et al
14
. 
The model, based on analysis of different flexible sigma 1 ligands determined that one 
basic amine flanked by two hydrophobic regions was necessary for binding (Figure 2.1). 
The distances between the basic amino group and the primary and secondary 
hydrophobic regions should be in the range of 6-10 Å and 2.5-3.9 Å, respectively
14
. In 
addition, the basic amino group could be a secondary or tertiary amine and each 
hydrophobic region tolerates steric bulk at those positions. More recently, a 3D model 









Figure 2.1. Glennon model for ligand binding to sigma receptors 
 
 With this model in mind, we searched through several structurally diverse ligands 









. Of these 
structures, we were most interested in the arylalkylamines and haloperiodol because we 
could easily modify the phenyl rings of these compounds with a photoreactive group. 
Synthetic arylalkylamine compounds that are targeted to the sigma receptors often utilize 
a piperazine ring as the basic amine moiety in the compound. The addition of a 
cyclohexyl ring to the piperazine moiety also appears to increase the binding affinity of 
these compounds
21
. This information along with the structure of haloperiodol led us to 
the design of two new possible photoaffinity ligands for sigma receptors (Figure 2.2). In 
our proposed structures, we have utilized a piperazine ring as outlined from the previous 
examples. Both ligands make use of an aryl azide photoreactive group due to its small 
size and facile synthesis from an aniline precursor. We also chose to vary the position of 
the alkyne handle on either structure to allow for the cyclohexyl moiety to be placed on 





receptors. Upon completion of the synthesis of both these compounds, we have attempted 
to label the sigma 1 receptor in live cells.   
 
Figure 2.2. Proposed structures of photoaffinity labels for sigma receptors 
compared to examples of arylalkylamines and haloperiodol. 
 
2.2 Experimental methods 
2.2.1 Probe 1 synthesis 
Starting with p-nitrobenzoic acid, intermediate 1 was synthesized under standard 
peptide coupling conditions with EDC and HOBt. Alkylation of 1 with Boc-piperazine to 
form 2 was followed by acid deprotection to yield piperazine 3. The alkyne handle was 
affixed to the scaffold by reacting piperazine 3 with propargyl amine under peptide 
coupling conditions to form alkyne 4. Reduction of the nitro group in alkyne 4 with tin 
(II) chloride (SnCl2) produced aniline 5, which was then converted to the aryl azide under 






Scheme 2.1. Synthesis of photoaffinity ligand probe 1. 
 
2.2.2 Probe 2 synthesis 
Similar to the strategy used previously, probe 2 was synthesized through the 
peptide coupled intermediate 1 from p-nitrobenzoic acid. Alkylation of compound 1 with 
cyclohexylpiperazine led to intermediate 6, which underwent SnCl2 reduction to yield 
aniline 7. Aryl azide 8 was synthesized as previously described utilizing Sandmeyer 
conditions from aniline 7. The amide of intermediate 8 was then alkylated under basic 







Scheme 2.2. Synthesis of photoaffinity ligand probe 2. 
2.3 Results and Discussion 
The original strategy for the synthesis of probe 1 and probe 2 was to utilize p-
azidobenzoic acid as the starting point for both probes. This would incorporate the 
photoreactive group immediately in the synthesis and facilitate the completion of these 
probes in 3-4 steps. However, following the successful peptide coupling with 3-
chloropropyl amine, it was found that the aryl azide moiety was not stable enough to 
survive the reflux conditions needed for the subsequent alkylation with Boc-piperazine or 
cyclohexylpiperzine. Therefore, the azido starting material was replaced with p-
nitrobenzoic acid, which would be more stable under reflux conditions and can later be 
converted to an aryl azide following reduction with SnCl2.  
The alkylation of the amide bond in compound 8 to yield photoaffinity ligand 
probe 2 was also a reaction of particular interest. The first attempts to complete the 
synthesis under mild basic conditions with potassium carbonate (K2CO3) or N,N-
diisopropylethylamine (Hunig’s base) were unsuccessful despite evidence in the literature 
for this transformation
22,23
. However, following the addition of the stronger base 





Probe 1 and probe 2 were sent to the Psychoactive Drug Screen Program at the 
University of North Carolina to evaluate their binding affinity towards the sigma 
receptors. Probe 1 was found to be slightly more selective towards the sigma 2 receptor 
over sigma 1, with binding affinities of 230 nM and 821 nM, respectively (Figure 2.3). 
Similarly, probe 2 was more selective for sigma 2 than sigma 1, but was found to have a 
much higher binding affinity towards both receptors (1.9 nM, 29 nM, respectively) 
(Figure 2.4). This increase in binding affinity was likely due to the addition of the 
cyclohexyl group found in compound probe 2, which agrees with literature precedent. 
Probe 2 was chosen as the lead compound for receptor labeling studies due to its high 
potency towards both sigma receptors. 
 
Figure 2.3.  Binding curves for photoaffinity ligand probe 1. a.) Sigma 1 binding. b.) 






Figure 2.4. Binding curves for photoaffinity ligand probe 2. a.) Sigma 1 binding. b.) 
Sigma 2 binding 
 
 To demonstrate specific labeling of the sigma receptors with probe 2, several 
different cell lines and the lysates from these cell lines were incubated with 
concentrations of probe varying from 0.1 nM up to 100 μM. These cell lines included 
HEK, sigma 1-transfected HEK, HeLa, sigma 1-transfected HeLa, MCF7, and primary 
rat cerebellar neurons, all of which have a high level of sigma 1 and sigma 2 receptor 
expression. Rat organs including the liver, brain, spine, and kidney were also incubated 
with probe to visualize these receptors in whole tissues. During the course of the 
experiment, some samples were irradiated with 365 nm light to crosslink the ligand its 
binding partner, while others were kept in the dark. Despite the potency of probe 2 for 
both sigma receptors, no significant labeling in any of these experiments was observed. 
In most cases there was no difference between the irradiated and non-irradiated samples. 
This could possibly be due to the aryl azide moiety not being in close enough proximity 
to the receptor to form a stable covalent bond. If the aryl azide moiety is in a large 





azide moiety could be facing into the pocket and react with solvent rather than the 
receptor.    
2.4 Conclusion 
 Probe 2 is a potent compound for the sigma receptors. Despite its affinity, the 
probe does not provide an effective method for labeling these receptors on live cells. 
Further iterations of the probe could utilize a longer linker between the piperazine moiety 
and the aryl azide, which might allow for labeling of the receptor by placing the aryl 
azide in closer proximity to a potential nucleophile.   
2.5 Materials and Methods 
2.5.1 General information 
All reagents, biological and chemical, were purchased through Fisher Scientific 
(Fair Lawn, NJ, USA).  All reactions involving air- and moisture-sensitive reagents were 
performed under an argon atmosphere using syringe-septum cap techniques.  DMF and 
CH2Cl2 were dried by storing over molecular sieves (4Å).  Analytical thin-layer 
chromatography (TLC) was carried out using Merck Silica gel 60 F254 aluminum sheets.  
Compounds were detected as single spots on TLC plates and visualized using UV light 
(254 or 366 nm) and ninhydrin.  Merck silica gel (35–70 mesh) was used for flash 
chromatography. 
1
H NMR spectra were recorded on a 400 MHz Bruker NMR 
spectrometer using the residual proton resonance of the solvent as the standard.  
Chemical shifts are reported in parts per million (ppm).  When peak multiplicities are 





triplet; q, quartet; m, multiplet.  Mass spectra were measured on a Waters ZQ device for 
LRMS. 
2.5.2 Synthesis of PAL for sigma receptors 
Synthesis of N-(3-chloropropyl)-4-nitrobenzamide (1) 
P-nitrobenzoic acid (2.0 g, 12 mmol), EDC (2.3 g, 12 mmol), and HOBt (1.8 g, 
12 mmol) were dissolved in dry CH2Cl2 (15 mL) under argon and stirred for 10 minutes. 
3-chloropropyl amine HCl (1.2 g, 9.2 mmol) and DIPEA (2.4 mL, 14 mmol) were 
dissolved in dry CH2Cl2 (5 mL) and added dropwise to the reaction mixture. After 
stirring the reaction overnight the solvent was removed and the residue was dissolved in 
EtOAc (50 mL). The organic layer was washed with 0.5 HCl (50 mL), saturated aq. 
NaHCO3 (2x25 mL), brine (25 mL), and dried with MgSO4. The organic layer was 
removed by rotary evaporation and column chromatography was performed with 2:1 
EtOAc:Hexanes as the mobile phase to yield 1.96 grams (90% yield) of an off white 
solid. 
1
H NMR (400 MHz, CDCl3) δ ppm 8.32 (d, J = 9.09 Hz, 2 H) 7.96 (d, J = 8.84 Hz, 2 H) 
6.51 (br s, 6 H) 3.69 (dt, J = 6.06, 3.03 Hz, 4 H) 2.13 - 2.22 (m, 2 H) 2.06 (s, 1 H) 
Synthesis of tert-butyl 4-(3-(4-nitrobenzamido)propyl)piperazine-1-carboxylate (2) 
To a stirring solution of 1 dissolved in DMF (10 mL) was added K2CO3 (0.870 g, 
6.27 mmol), KI (0.170 g, 1.05 mmol), and Boc-piperazine (0.580 g, 3.14 mmol). The 
reaction mixture was heated to 80˚C and stirred under argon for 18 hours. After cooling 
to room temperature the mixture was poured into H2O (20 mL) and was extracted with 
EtOAc (3 x 25 mL). The combined organic layers were washed with brine (25 mL) and 





chromatography was performed using 4:1 CH2Cl2:MeOH as the mobile phase to obtain 
0.492 grams (60% yield) of a white solid. 
1
H NMR (400 MHz, CDCl3) δ ppm 8.30 - 8.33 (m, 2 H) 7.99 (d, J = 8.34 Hz, 2 H) 3.63 
(q, J = 5.81 Hz, 2 H) 3.47 (br s, 4 H) 2.43 - 2.72 (m, 5 H) 1.89 (br. s., 2 H) 1.48 (s, 9 H) 
Synthesis of 4-nitro-N-(3-(piperazin-1-yl)propyl)benzamide (3) 
Boc-Piperzine 2 (0.170 g, 0.433 mmol) was dissolved in 3 M anhydrous HCl (2 
mL) and stirred for 1.5 hours at room temperature. The solvent was removed via rotary 
evaporation to yield 0.131 grams (92% yield) of a white solid. The compound was used 
without further purification. 
1
H NMR (400 MHz, CD3OD) δ ppm 8.29 - 8.37 (m, 2 H) 8.02 - 8.10 (m, 2 H) 3.47 - 3.70 
(m, 10 H) 2.06 - 2.18 (m, 2 H) 1.53 - 1.61 (m, 2 H) 
Synthesis of 4-nitro-N-(3-(4-(prop-2-yn-1-yl)piperazin-1-yl)propyl)benzamide (4) 
Piperazine 3 (0.500 g, 1.52 mmol) and DIPEA (784 μL, 4.56 mmol) was 
dissolved in dry CH2Cl2 (4 mL) under argon at 0˚C. Propargyl bromide (143 μL, 1.52 
mmol) dissolved in CH2Cl2 (1 mL) was then added dropwise. The solution was allowed 
to warm to room temperature and stir for 16 hours. The solvent was removed in vacuo 
and the residue was dissolved in EtOAc (40 mL). The organic layer was washed with 
NaHCO3 (2 x 20 mL), brine (20 mL), and dried with MgSO4. The solvent was removed 
via rotary evaporation to and column chromatography was performed using 4:1 
CH2Cl2:MeOH as the mobile phase to give 0.188 grams (38%) of a yellow oil. 
1
H NMR (400 MHz, CD3OD) δ ppm 8.30 - 8.38 (m, 2 H) 8.00 - 8.07 (m, 2 H) 3.47 (t, J = 
6.95 Hz, 2 H) 2.60 - 2.72 (m, 3 H) 2.46 - 2.57 (m, 2 H) 1.79 - 1.90 (m, 2 H) 





Alkyne 4 (0.230 g, 0.670 mmol) dissolved in EtOH (5 mL) was treated with 
SnCl2 (0.470 g, 2.10 mmol) and heated to reflux for 16 hours. The mixture was allowed 
to cool to room temperature, poured onto ice, and was made basic with the addition of 1 
N NaHCO3. The solution was carefully filtered through celite and the filter cake was 
washed several times with CH2Cl2. The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3x15 mL). The organic layers were combined, washed with brine 
(25 mL), dried with MgSO4, and the solvent was removed via rotary evaporation to yield 
73 mg (35%) of a yellow oil.  The product was used without further purification.  
1
H NMR (400 MHz, CD3OD) δ ppm 7.60 (d, J = 8.59 Hz, 2 H) 6.68 (d, J = 8.59 Hz, 2 H) 
3.40 (t, J = 6.82 Hz, 14 H) 2.61 - 2.76 (m, 4 H) 2.46 - 2.54 (m, 2 H) 1.77 - 1.86 (m, 2 H) 
Synthesis of Probe 1 
 
To a 0˚C solution of 5 (69 mg, 0.23 mmol) dissolved in 2 N HCl (5 mL) was 
added slowly a solution of NaNO2 (16 mg, 0.24 mmol) in water (300 μL). After stirring 
for 15 minutes, the reaction vessel was covered with aluminum foil and a solution of 
NaN3 (15 mg, 0.24 mmol) in water (600 μL) was added dropwise and the reaction was 
allowed to warm to room temperature and stirred for 4 hours. The mixture was poured 
slowly into H2O (10 mL), basified with 1 N NaOH, and extracted with EtOAc (3x20 
mL). The combined organic layers were washed with brine, dried with MgSO4, and the 
solvent was removed via rotary evaporation. Column chromatography was performed 
using 4:1 CH2Cl2: MeOH as the mobile phase to obtain 60 mg (81% yield) of a yellow 
product.  
1
H NMR (400 MHz, CD3OD) δ ppm 7.87 (d, J = 8.84 Hz, 2 H) 7.17 (d, J = 8.84 Hz, 2 H) 





LCMS (ESI-TOF) Calc for C17H22N6O [M+1]; 327.40, Found: 327.41 
Synthesis of N-(3-(4-cyclohexylpiperazin-1-yl)propyl)-4-nitrobenzamide (6) 
To a stirring solution of 1 (0.710 g, 2.97 mmol) dissolved in dry CH3CN (20 mL) 
was added K2CO3 (0.820 g, 5.94 mmol), KI (50.0 mg, 0.297 mmol), and 
cyclohexylpiperzine (1.00 g, 5.94 mmol). The reaction mixture was heated to reflux and 
stirred under argon for 18 hours. After cooling to room temperature the mixture was 
evaporated to dryness and water (20 mL) was added to the residue. The aqueous phase 
was extracted with EtoAc (3 x 25 mL) and the combined organic layers were washed 
with brine (25 mL) and dried with MgSO4. The organic layer was removed using rotary 
evaporation and. column chromatography was performed using 4:1 CH2Cl2:MeOH as the 
mobile phase to yield 0.616 grams (56% yield) of a white solid. 
1
H NMR (400 MHz, CDCl3) δ ppm 8.27 - 8.32 (m, 2 H) 8.02 (d, J = 8.59 Hz, 2 H) 3.62 
(d, J = 5.31 Hz, 2 H) 3.51 (s, 1 H) 2.47 - 2.69 (m, 7 H) 2.22 - 2.33 (m, 1 H) 1.77 - 1.89 
(m, 6 H) 1.67 (d, J = 12.63 Hz, 1 H) 1.06 - 1.34 (m, 6 H)  
Synthesis of 4-amino-N-(3-(4-cyclohexylpiperazin-1-yl)propyl)benzamide (7) 
Nitro compound 6 (0.470 g, 1.26 mmol) dissolved in EtOH (15 mL) was treated 
with SnCl2 (0.833 g, 3.69 mmol) and stirred at reflux for 16 hours. The mixture was 
allowed to cool to room temperature, poured onto ice, and was made basic with the 
addition of 1 N NaHCO3. The solution was carefully filtered through celite and the filter 
cake was washed several times with CH2Cl2. The layers were separated and the aqueous 
layer was extracted with CH2Cl2 (3x15 mL). The organic layers were combined, washed 





evaporation to obtain 0.367 grams (84% yield) of product.  The product was used in the 
next step without further purification. 
1
H NMR (400 MHz, CD3OD) δ ppm 7.60 (d, J = 8.59 Hz, 2 H) 6.64 - 6.71 (d, 2 H) 5.51 
(s, 1 H) 3.40 (s, 2 H) 2.45 - 2.82 (m, 8 H) 2.33 (d, J = 3.03 Hz, 1 H) 1.96 (d, J = 10.61 
Hz, 2 H) 1.77 - 1.89 (m, 4 H) 1.67 (d, J = 12.63 Hz, 1 H) 1.09 - 1.37 (m, 6 H) 
Synthesis of 4-azido-N-(3-(4-cyclohexylpiperazin-1-yl)propyl)benzamide (8) 
To a 0˚C solution of aniline 7 (0.290 g, 0.842 mmol) dissolved in 2 N HCl (5 mL) 
was added slowly a solution of NaNO2 (60.0 mg, 0.859 mmol) in water (300 μL). After 
stirring for 15 minutes, the reaction vessel was covered with aluminum foil and a solution 
of NaN3 (56.0 mg, 0.859 mmol) in water (600 μL) was added dropwise and the reaction 
was allowed to warm to room temperature and stirred for 2 hours. The mixture was 
poured slowly into water (10 mL), basified with 1 N NaOH, and extracted with EtOAc 
(3x20 mL). The combined organic layers were washed with brine, dried with MgSO4, and 
the solvent was removed via rotary evaporation to obtain 0.357 grams (84% yield) of a 
off white solid. The product was used without further purification. 
1
H NMR (400 MHz, CD3OD) δ ppm 7.86 (d, J = 8.59 Hz, 2 H) 7.16 (d, J = 8.59 Hz, 2 H) 
3.44 (t, J = 6.82 Hz, 2 H) 2.43 - 2.75 (m, 8 H) 2.28 (d, J = 3.28 Hz, 1 H) 1.94 (d, J = 
11.12 Hz, 2 H) 1.79 - 1.88 (m, 4 H) 1.67 (d, J = 12.63 Hz, 1 H) 1.05 - 1.37 (m, 6 H) 
Synthesis of probe 2 
Azido compound 8 (0.130 g, 0.350 mmol) and potassium tert-butoxide (60.0 mg, 
0.525 mmol) was dissolved in dry DMF (3 mL) under argon at 0˚C. Propargyl bromide 
(32.0 μL, 0.420 mmol) dissolved in DMF (0.5 mL) was then added dropwise and the 





poured into water (30 mL) and extracted with EtOAc (3x25 mL). The combined organic 
fractions were washed with brine (25 mL), dried with MgSO4, and the solvent was 
removed via rotary evaporation. Column chromatography was performed using 4:1 
CH2Cl2:MeOH as the mobile phase to yield 86 mg (61% yield) of a yellow oil. 
1
H NMR (400 MHz, CDCl3) δ ppm 7.52 (br s, 2 H) 7.05 - 7.12 (m, 2 H) 5.32 (s, 1 H) 
1.83 (br s, 4 H) 1.08 - 1.33 (m, 6 H) 
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SILENT, FLUORESCENT LABELING OF THE DOPAMINE AND SEROTOIN 
TRANSPORTERS WITH MULTIFUNCTIONAL PROBES 
3.1 Introduction 
As discussed previously in chapter 1, our lab has developed a small, minimally 
perturbing and multifunctional probe that has allowed us to label endogenous neuronal 
receptors. Nanoprobe 1, bearing a use dependant spermine ligand, was specifically design 
to label and track calcium permeable AMPA receptors. To expand the use of our 
nanoprobe technology, we can exploit the modular design of the probe to substitute 
portions of the probe to allow it to function differently. In this work, we were particularly 
interested in replacing the spermine ligand for other pharmacophores to target other 
receptors of interest. Two important molecular targets that can be studied using this 
method are the presynaptic dopamine and serotonin transporters. 
The dopamine transporter (DAT) regulates levels of dopamine at the synapse and 
is a target for widely abused psychostimulants such as cocaine and amphetamines. DAT 




 dependent transporter family, which includes the serotonin 
transporter (SERT) and norepinephrine transporter
1
. Dopamine is an important 
neurotransmitter that modulates several processes including attention, arousal, cognition, 
reward, and motor activity
2
.  However, disruption of normal dopamine signaling has been 







, and attention deficit hyperactivity disorder
6
. DAT is 
particularly challenging to study due to the lack of an efficient antibody
2
 and the 







The SERT is an integral membrane protein expressed in neurons of the raphe 
nuclei in the brain. Similar to the function of the DAT, SERT is responsible for rapid 
clearance of the neurotransmitter serotonin from the synaptic cleft, thereby terminating 
the chemical signal transduction in serotonergic neurons
8
. As a result, SERT plays a 
critical role in centrally mediated functions associated with serotonin such as sleep, 
mood, and appetite
9
. This transporter is also the primary target for selective serotonin 
reuptake inhibitors and tricyclic antidepressants, which are prescribed for the treatment of 
depressive disorders and anxiety
10
. These drugs are designed to bind to the SERT and 
prevent reuptake of serotonin at the synapse back into the cell. However, despite proven 
clinical success, the mechanisms underlying why these drugs are effective remains 
elusive. 
Previous work in the Newman lab was toward the development of two 
fluorescently tethered ligands for the DAT and SERT
11,12,13
.  One high affinity 
fluorescent probe developed by Cha et al (JHC-1-64) utilized a tropane analogue of 
cocaine to enable visualization of the DAT in live cells (Figure 3.1)
12
. This new probe 
contained a rhodamine fluorophore that had both higher photostability and quantum yield 
than previously reported probes
14
. In addition, JHC 1-64 applied to neuronal culture 
revealed a uniform distribution of the DAT labeling of somas, extensions, and 
varicosities
11
. The Newman group also designed a fluorescent tool based off the 
antidepressant drug Citalopram, which can give insight into the mechanisms underlying 
depression (Figure 3.1)
13
. Fluorescent compound 8 was used to demonstrate the specific 
labeling of SERT in a HEK293 cell line expressing hSERT with EGFP fused to the N-















 Although both ligands have proven to be useful fluorescent tools for labeling 
DAT and SERT, their effectiveness is somewhat limited as they must occupy the binding 
site for visualization of the receptors. As discussed previously in chapter 1, occupation of 
a binding site by an agonist or antagonist can cause conformational changes or 
differential trafficking patterns. In the case for the DAT, it has been determined that not 
all dopamine uptake blockers are cocaine-like and could possibly prove as effective 
medications without addictive liability. Understanding the mechanisms of the differences 





medications that are effective for the treatment of cocaine and methamphetamine 
addiction, as well as other neuropsychiatric disorders
15
. Since the fluorescent compound 
JHC 1-64 blocks the binding site, it would prevent other drugs such as cocaine or 
methamphetamine from binding. Hence, although constitutive activity of the DAT could 
be visualized, the effects of these drugs on the trafficking of DAT cannot.  
3.1.1 Probe design 
 In collaboration with the Newman and Gether labs, we designed new fluorescent 
probes for the DAT and SERT utilizing our nanoprobe technology. In this work, we have 
redesigned nanoprobe 1 to label DAT and SERT by replacing the use dependant 
spermine ligand with a tropane analogue of cocaine and the antidepressant drug 
citalopram, respectively (Figure 3.2). Based on the previous binding data and imaging 
studies conducted by the Newman lab, we believe these new ligands will give specificity 
for these receptors and therefore allow for visualization on live cells. We have also 
replaced the Cy3 chromophore from nanoprobe 1 with a sulfonylrhodamine dye to 
display the modular nature of our nanoprobe technology. The synthesis of these probes 
should allow for silent labeling of endogenous DAT and SERT and expand the toolbox 






Figure 3.2. Conversion of nanoprobe 1 to DAT and SERT nanoprobes. 
 
3.2 Experimental Methods 
3.2.1 Probe synthesis 
Borrowing from synthetic precedent
16
, the probe was synthetically elaborated 
commencing with the nitroindoline core to provide two orthogonal protecting groups for 
further chemical modification. The tert-butyl ester of the nitroindoline core 1 was 
selectively deprotected under acidic conditions to yield carboxylic acid 2. Carboxylic 
acid 2 was functionalized with rhodamine-cadaverine under standard peptide coupling 
conditions to form the fluorescent intermediate 3. Rhodamine intermediate 3 then 
underwent basic hydrolysis to deprotect the methyl ester moiety to produce carboxylic 
acid 4. Carboxylic acid 4 was treated with either dopamine ligand (MFZ-15-94) or 





of the dopamine (SM-V-61) and serotonin (SM-V-37) nanoprobes in 30% yield for each 
probe (Scheme 3.1).  
 
Scheme 3.1. Synthesis of DAT and SERT Nanoprobes from indoline 1. 
3.3 Results and Discussion 
 The synthesis of both the DAT and SERT nanoprobes was based on previously 
prepared nanoprobe 1. The tert-butyl ester of indoline 1 could selectively be deprotected 
under mild acidic conditions with trifluoroacetic acid (TFA). The peptide coupling of the 
rhodamine fluorophore to carboxylic acid 2 proved to be challenging. Under standard 
peptide coupling conditions with EDC and HOBt, the reaction was found to take upwards 
of 3 days to produce a majority of the fluorescent intermediate 3. This could be due to 
unfavorable steric interactions between carboxylic acid 2 and the rhodamine ligand, 
despite the fact that a 6 carbon linker was utilized. In the future, it might be interesting to 





rhodamine ligand. To circumvent this issue, higher equivalents of EDC and HOBt were 
utilized to promote the production of intermediate 3. This not only improved the yield of 
the reaction, but also lowered the reaction time to 18 hours. Completion of both 
nanoprobes was done through the peptide coupling of carboxylic acid 4 with dopamine or 
serotonin ligands supplied by the Newman lab. Carboxylic acid 4 proved to be more 
reactive than carboxylic acid 2, likely due to less steric crowding at that position.  
 Upon completion of the DAT (SM-V-61) and SERT (SM-V-37) nanoprobes, they 
were sent to the Gether lab in Copenhagen for experiments to collect binding data and 
visualization of both receptors. We were interested in determining the binding affinity to 
ensure that the steric bulk from the nanoprobe structure did not completely disrupt the 
binding of either the dopamine or serotonin ligand utilized. As shown in table 3.1 and 
3.2, both SM-V-61 and SM-V-37 displayed lower binding affinities towards their 
respective targets when compared to the previously synthesized fluorescent ligands from 
the Newman lab. However, to our delight, both nanoprobes were found to retain affinity 
for the DAT and SERT (244 nM and 202 nM, respectively), which should allow for 
visualization of these receptors on live cells. 
Table 3.1. Binding affinity for SM-V-61 for the DAT. Uptake values were determined 
from uptake inhibition experiments in transfected COS-7 cells utilizing [
3
H]dopamine. 
Binding affinity was determined from competition binding experiments on intact COS-7 
cells using [
3
H] CFT (2β-carbomethoxy-3β-94-fluorophenyl)tropane) as the radioligand. 
 Uptake (Ki nM) 
DAT 
Binding (Ki nM) 
DAT 
SM-V-61 529 244 







Table 3.2. Binding affinity for SM-V-37 for the SERT. Uptake values were determined 
from uptake inhibition experiments in transfected COS-7 cells utilizing [
3
H]5-HT. 
Binding affinity was determined from competition binding experiments on intact COS-7 
cells using [
3
H] S-citalopram as the radioligand. 
 Uptake (Ki nM) 
DAT 
Binding (Ki nM) 
DAT 
SM-V-37 603 202 
Compound 8 225 N/A 
 
 To demonstrate specific labeling of DAT with SM-V-61, we utilized a HEK293 
cell line stably expressing hDAT with EGFP fused to the N-terminus. Cells were 
incubated with 20 nM of SM-V-61 for 20 minutes at 37˚C with or without the specific 
DAT inhibitor nomifensine. As shown in Figure 3.3, live cell imaging using confocal 
microscopy revealed a uniform distribution of SM-V-61 (red) at the cell surface only 
where EGFP-DAT (green) was seen. The labeling of DAT by SM-V-61 is completely 
blocked in the presence of nomifensine as there is no fluorescence observed at the cell 
surface in the red channel. In addition, the transmission image shows that there are some 
cells that have not been transfected with the EGFP-DAT and SM-V-61 does not seem to 
label these cells. This evidence suggests that SM-V-61 is specific towards the EGFP-
DAT and is not just labeling the cell surface.  Another representation of EGFP-DAT 
labeling by SM-V-61 is shown in Figure 3.4. These images show complete labeling of the 










Figure 3.4. Overlay image of EFGP-DAT labeling by SM-V-61 in HEK293 cells. 
 
 To demonstrate specific labeling of SERT with SM-V-37, similar conditions were 
followed as previously discussed. A HEK293 cell line stably expressing EGFP-SERT 
was incubated with 20 nM of SM-V-37 for 20 minutes in the presence or absence of a 





V-37 only in the areas of green fluorescence from EGFP-SERT. Receptor labeling is also 
completely blocked in the presence of paroxetine, showing no fluorescence in the red 
channel (Figure 3.5). These labeling results are also confirmed by the overlay image as 
seen in Figure 3.6, where the yellow color can be seen evenly distribution around the cell 
surface. 
 
Figure 3.5. Visualizing SM-V-37 binding to hDAT in HEK293 cells. 
 
 






 The results of the fluorescent imaging of both nanoprobes suggest that they are 
specific towards their targeted receptor in transfected HEK cells. The labeling is due to 
the specificity of the DAT and SERT ligands employed based on the block of the red 
fluorescence in the presence of an inhibitor as well as a lack of labeling observed in non-
transfected cells. Currently, work is being done in the Gether lab to optimize conditions 
for ligand displacement following uncaging of the nitroindoline core utilizing UV light. If 
fluorescence is still observed after uncaging, this would suggest the nanoprobe is 
covalently bond to the receptor of interest and the binding site should be unhindered. 
Future work will be to utilize either nanoprobe to label endogenous DAT or SERT in live 
neurons, enabling visualization of these receptors in their natural state. 
3.4 Conclusion 
 The DAT and SERT nanoprobes synthesized in this work display the modular 
nature of our nanoprobe technology. The addition of either a DAT or SERT ligand to the 
nanoprobe scaffold maintained affinity towards either receptor (244 nm, 202 nm, 
respectively) and also allowed for visualization of these receptors in transfected HEK 
cells. Further studies conducted with cultured neurons will validate these probes as new 
tools available for neurobiologists to study both endogenous DAT and SERT. 
3.5 Materials and Methods 
3.5.1 General information 
All reagents, biological and chemical, were purchased through Fisher Scientific 
(Fair Lawn, NJ, USA).  All reactions involving air- and moisture-sensitive reagents were 





CH2Cl2 were dried by storing over molecular sieves (4 Å).  Analytical thin-layer 
chromatography (TLC) was carried out using Merck Silica gel 60 F254 aluminum sheets.  
Compounds were detected as single spots on TLC plates and visualized using UV light 
(254 or 366 nm) and KMnO4 or ninhydrin.  Merck silica gel (35–70 mesh) was used for 
flash chromatography.  
1
H NMR spectra were recorded on a 400 MHz Bruker NMR 
spectrometer using the residual proton resonance of the solvent as the standard.  
Chemical shifts are reported in parts per million (ppm).  When peak multiplicities are 
given, the following abbreviations are used: s, singlet; bs, broad singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet. Mass spectra were measured on a Waters ZQ device for 
LRMS and at the UMass Mass Spectrometry facility for HRMS.   
3.5.2 Synthesis of DAT and SERT Nanoprobes 
Synthesis of 2-(6-acrylamidohexanamido)-5-(4-(2-methoxy-2-oxoethoxy)-7-
nitroindolin-1-yl)-5-oxopentanoic acid (2) 
Indoline 1 (0.200 g, 0.331 mmol) was dissolved in a 10% TFA/CH2Cl2 solution (2 
mL) and stirred for 12 hours at room temperature. The solvent was removed via rotary 
evaporation to yield 0.202 grams (92% yield) of a yellow oil, was used in the next step 
without further purification. 
1





Carboxylic acid 2 (41 mg, 0.075 mmol), EDC (26 mg, 0.14 mmol), and HOBt (21 





minutes.  Rhodamine cadaverine (45 mg, 0.069 mmol) and DIPEA (24 μL, 0.14 mmol) 
were dissolved in dry DMF (1 mL) and added slowly to the reaction mixture over 2 
minutes.  After stirring the reaction for 16 hours the solvent was removed via rotary 
evaporation and column chromatography was performed utilizing 80:10:10 
CH2Cl2:CH3CN:MeOH as eluent to give 50 mg (62% yield) of a purple oil. 




Methyl ester 3 (40 mg, 0.034 mmol) was dissolved in MeOH (1 mL) and treated 
with 1 M NaOH (67 μL).  The reaction mixture was stirred at room temperature for 4 
hours then neutralized with 1 M citric acid (67 μL) and concentrated via rotary 
evaporation.  The residue was diluted with water (2 mL), acidified to pH 2 with 1 M 
citric acid, and extracted with CH2Cl2 (3 x 4 mL).  The organic layer was dried with 
MgSO4, filtered, and the solvent removed via rotary evaporation to obtain 38 mg (96% 
yield) of a purple oil. The product was used without further purification. 
LCMS (ESI-TOF) Calc for C57H72N8O15S2 [M+1]; 1173.36, Found: 1173.20 
Synthesis of Dopamine Nanoprobe (SM-V-61) 
Carboxylic acid 4 (21 mg, 0.018 mmol), EDC (6.0 mg, 0.032 mmol), and HOBt 
(5.0 mg, 0.032 mmol) were dissolved in dry DMF (1 mL) under argon and stirred for 10 
minutes.  Dopamine ligand (MFZ15-94) (8.0 mg, 0.016 mmol) and DIPEA (11 μL, 0.063 
mmol) were dissolved in dry DMF (1 mL) and added slowly to the reaction mixture.  





and the product was purified by preparative-HPLC to obtain 7.9 mg (30% yield) of a  
dark pink solid. (XBridge Prep C18 5μm (10 x 100 mm) column: H2O and CH3CN/0.1% 
formic acid as the mobile phase. Retention time=23.89 minutes) 
1
H NMR (500 MHz, CD3OD) δ ppm 8.54 (d, J = 1.68 Hz, 1 H) 8.45 (s, 8 H) 7.99 (dd, J = 
7.93, 1.83 Hz, 1 H) 7.63 (d, J = 9.00 Hz, 1 H) 7.41 (d, J = 7.93 Hz, 1 H) 7.31 - 7.35 (m, 2 
H) 7.09 (dd, J = 8.32, 1.91 Hz, 1 H) 6.98 - 7.03 (m, 2 H) 6.89 (d, J = 9.46 Hz, 2 H) 6.83 
(d, J = 2.14 Hz, 2 H) 6.64 (d, J = 9.16 Hz, 1 H) 6.07 - 6.10 (m, 2 H) 5.51 (dd, J = 8.54, 
3.51 Hz, 1 H) 4.59 (s, 2 H) 4.14 - 4.25 (m, 3 H) 3.56 (q, J = 7.12 Hz, 8 H) 3.31 (s, 3 H) 
3.08 - 3.14 (m, 6 H) 2.91 (t, J = 6.87 Hz, 2 H) 2.60 (br. s., 1 H) 2.38 - 2.54 (m, 4 H) 2.25 
- 2.32 (m, 2 H) 2.16 (t, J = 7.40 Hz, 3 H) 2.08 (d, J = 5.95 Hz, 1 H) 1.90 - 2.03 (m, 1 H) 
1.79 - 1.88 (m, 2 H) 1.73 (d, J = 11.75 Hz, 1 H) 1.48 - 1.56 (m, 2 H) 1.31 - 1.45 (m, 11 
H) 1.16 - 1.29 (m, 23 H) 
LCMS (ESI-TOF) Calc for C82H109Cl2N12O16S2 [M+1]
+
 ; 1653.85, Found: 1653.90 
HRMS (ESI-TOF) Calc for C82H109Cl2N12O16S2 [M+2]
+
; 827.349, Found: 827.348 
Synthesis of Serotonin Nanoprobe (SM-V-37) 
Carboxylic acid 4 (23 mg, 0.020 mmol), EDC (7.0 mg, 0.036 mmol), and HOBt 
(6.0 mg, 0.036 mmol) were dissolved in dry DMF (1 mL) under argon and stirred for 10 
minutes.  Serotonin ligand (VK03-45) (9.0 mg, 0.018 mmol) and DIPEA (12 μL, 0.069 
mmol) were dissolved in dry DMF (1 mL) and added slowly to the reaction mixture.  
After stirring the reaction for 16 hours the solvent was removed via rotary evaporation 
and the product was purified by preparative-HPLC to obtain 8.3 mg (30% yield) of a dark 
pink solid. (XBridge Prep C18 5μm (10 x 100 mm) column: H2O and CH3CN/0.1% 





LCMS (ESI-TOF) Calc for C85H111FN11O16S2 [M+1]
+
 ; 1625.98, Found: 1625.8 
HRMS (ESI-TOF) Calc for C82H109Cl2N12O16S2 [M+1]
+
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DEVELOPING A MODULAR KIT FOR TRACLESS LABELING OF 
ENDOGENOUS RECEPTORS 
4.1 Introduction 
The synthesis of the DAT and SERT nanoprobes discussed in Chapter 3 showed 
how the modular design of our nanoprobe technology could be utilized to target different 
receptors of interest. With an eye towards making this technique more general for other 
scientists who are interested in labeling endogenous receptors, we have designed and 
synthesized a new nanoprobe bearing an alkyne handle in place of a specific ligand.  The 
alkyne moiety allows for ligand diversity at that point by utilizing a highly specific 1,3-
dipolar cycloaddition reaction (click) with a ligand containing an azido linker.  In 
addition, a free carboxylic acid in the molecule facilitates fluorophore diversity through 
reactions with commercially available amine terminated dyes (Figure 4.1). This modular 
and functional intermediate molecule allows for a vast library of compounds with 
different fluorescent profiles to be synthesized in a  relatively short period of time.  As a 
proof of concept, we functionalized a pharmacophore with an azido linker and then 
reacted it with the alkyne nanoprobe scaffold. Upon successful completion of the click 
reaction, the probe was then be used to fluorescently label a receptor of interest. One 
particular target of interest in our lab and in the field of neurobiology are the postsynaptic 






Figure 4.1. Structure of the alkyne based nanoprobe. This new probe will allow for 
ligand diversity through click reactions with a pharmacophore containing an azido-
moiety. 
 
The NMDA receptor is a subtype of glutamate receptor that is believed to be 
involved in processes of synaptic plasticity and memory formation
1
. In the hippocampus, 
NMDA receptors are tetrameric complexes composed of the NR1 subunit and a mixture 
of the two NR2 subunits, NR2A and NR2B, which are needed to form a functional 
ionotopic receptor
2
. Out of the three types of glutamate receptors, NMDA receptors are 
generally the most permeable to calcium ions. Thus, overactivation of these receptors 
result in excitotoxic neuronal cell death due to excess calcium influx
3
. It is known that 
several neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, 
ALS, as well as acute disorders including stroke and epilepsy, share a final common 
pathway to neuronal injury due to overstimulation of glutamate receptors
4
. Therefore, 
NMDA receptor pharmacophores have become a topic of interest for potential 





4.1.1 Probe design 
 The strategy that we employed for the synthesis of the alkyne based nanoprobe 
was slightly altered from the previously discussed nanoprobe scaffolds. Previously, the 
indoline scaffold was functionalized with a fluorophore first, then followed up two steps 
later with the peptide coupling of a specific pharmacophore. Here, we decided to attach 
our alkyne handle first, which would allow for modification with a fluorophore as the last 
step. This would allow for the alkyne nanoprobe to be reacted with a variety of 
fluorophores and produce an alkyne based probe with a multitude of colors and 
fluorescent profiles. 
 In collaboration with Dr. Doug Johnson at Pfizer Neuroscience (Cambridge, MA), 
we have devised a method to target NMDA receptors by utilizing a ketamine based 
ligand to react with our nanoprobe. Ketamine is a well-established anesthetic drug that 
has been in use for 50 years
5
. Ketamine acts as a non-competitive antagonist on NMDA 
receptors, where it binds at the phencyclidine (PCP) binding site
6
. The PCP binding site 
is localized within the receptor channel and partially overlaps with the magnesium 
binding site. Ketamine not only blocks the open channel and reduces the mean open time; 
it also decreases the frequency of channel opening by allosteric mechanisms
7
. Ketamine 
is often used as a racemic mixture, however, the S(+)-isomer has a 3-4 times higher 
affinity than the R-enantiomer
8
. To date, there have been limited structure-activity 
relationships for analogues of ketamine. Work by Jose et al. was aimed at the 
development of ketamine ester prodrugs for use as short-acting anestetics
9
. Several 
analogues of ketamine were synthesized by varying the length of the alkyl chain off the 





of each compound was not determined, their anesthetic effects were compared to 
ketamine in a rat infusion study. The short-chain aliphatic ester analogues broadly 
retained desirable anesthetic and analgesic activities, likely due to binding at the same 
site as the parent compound
9
. In all cases, the compounds conserved the secondary amine 
contained in ketamine, which is needed for a crucial interaction with asparagines in the 
NMDA receptor binding site
10,11,12
. Using this information we envisioned synthesizing a 
ketamine analogue containing an azido moiety through an extended alkyl chain (Figure 
4.2b). This would conserve the basic secondary amine for binding and also extend the 
pharmacophore away from the alkyne nanoprobe to reduce unfavorable steric interactions 
between the receptor and probe. 
 
Figure 4.2. Structure of ketamine analogues. a.) Ester prodrugs of ketamine
9
. b.) 







As discussed in the previous chapter, the nitroindoline core was synthesized 
following literature precedent
13
. The nitroindoline core 1 underwent base hydrolysis to 
deprotect the methyl ester providing carboxylic acid 2.  Carboxylic acid 2 was coupled to 
propargyl amine using standard peptide coupling conditions to provide the alkyne-
containing nanoprobe scaffold 3.  Alkyne nanoprobe 3 was subsequently treated with 
trifluoroacetic acid to afford carboxylic acid 4, which is the alkyne nanoprobe scaffold 
that will allow for a library of these probes to be synthesized (Scheme 4.1). 
 
Scheme 4.1. Synthesis of alkyne nanoprobe 4 from indoline core 1. 
 
To complete the synthesis of the ketamine based nanoprobe, carboxylic acid 4 





ketamine analogue was functionalized by alkylation with 1-azido-6-bromohexane to 
afford compound 6, which is then reacted with fluorescent probe 5 under standard “click” 
conditions to produce the final ketamine based nanoprobe SM-V-127 (Scheme 4.2).  
 
Scheme 4.2. Synthesis of ketamine based nanoprobe to target post synaptic NMDA 
receptors 
 
4.3 Results and Discussion 
 The synthesis of the alkyne nanoprobe was slightly altered when compared to the 
previously discussed DAT and SERT nanoprobes in Chapter 3. Here, we peptide coupled 
the alkyne ligand first to allow for deprotection of the tert-butyl ester, which would leave 
a free carboxylic acid that could then be reacted with any amine terminated dye. 
Following base hydrolysis of the methyl ester in indoline 1, alkyne nanoprobe 2 was 





compound because a longer linker on the pharmacophore could be utilized to extend the 
ligand out from the alkyne nanoprobe scaffold.  
 Following the synthesis of alkyne nanoprobe 4, we chose to functionalize the 
probe with the sulfonyl rhodamine fluorophore utilized in the previous chapter because of 
its high quantum yield and the reaction conditions for this transformation has been 
optimized. Fluorescent compound 5 would allow for a multitude of nanoprobes targeting 
different receptors to be synthesized rapidly through copper mediated click reactions with 
pharmacophores containing an azido handle. As discussed previously, we chose to target 
glutamatergic NMDA receptors by utilizing a ketamine based pharmacophore with an 
azido linker, which was synthesized by alkylating (S)-2-amino-2-(2-chlorophenyl) 
cyclohexanone with 1-azido-6-bromohexane. Although a primary amine undergoing an 
alkylation under reflux conditions would normally be expected to proceed smoothly, the 
yield for the reaction was found to be quite poor. This may be due to the amine being 
bonded to a quaternary carbon, leading to unfavorable steric interactions. The addition of 
KI to encourage SN2 displacement of the alkyl halide only slightly improved the yield of 
the reaction. Fluorescent compound 5 was reacted with azido ketamine analogue 6 under 
standard click reaction conditions using copper iodide and sodium ascorbate to produce 
the ketamine based nanoprobe SM-V-127 in 61% yield. The click reaction showed an 
improved yield and fewer side products observed over the previously synthesized DAT 
and SERT nanoprobes discussed in Chapter 3. This successful reaction displays how a 






    Labeling studies utilizing the ketamine nanoprobe were conducted on Chinese 
hamster ovary (CHO) cells stably transfected with an inducible vector containing the 
NR1A/NR2B NMDA receptor subunits. As discussed previously, ketamine is an open 
channel blocker of NMDA receptors and will require the addition of glutamate and 
glycine in order to open the binding site. The NMDA transfected cells were incubated 
with 20 μM of ketamine nanoprobe SM-V-127 with or without the parent compound 
ketamine and images were acquired immediately to visualize any background 
fluorescence or labeling. Without any agonist added, no labeling should be seen due to 
the binding site being closed to the ligand. In both cases, minimal background 
fluorescence was observed for SM-V-127 in the presence or absence of ketamine, as 
expected (Figure 4.3). As demonstrated in Figure 4.4, following the addition of glutamate 
and glycine, distinct fluorescent labeling is observed for SM-V-127 and is completely 
blocked in the presence of ketamine itself. Cell labeling can be observed with probe 
concentrations as low as 100 nM and as short as 2.5 minutes following the addition of the 
agonists. The imaging results suggest that labeling is due to the specificity of the 
pharmacophore attached to the nanoprobe scaffold as fluorescent is blocked by the parent 
compound. Further imaging studies are being conducted to determine how specific the 
ketamine probe is for the NMDA receptors. This will be done by the addition of 
antibodies for the NR1A/NR2B subunits following labeling with the ketamine 
nanoprobe. If visualization of the antibodies and nanoprobe colocalize, it would indicate 
that the nanoprobe is likely labeling NMDA receptors. In-gel fluorescence experiments 
are also being run in parallel with the CHO cell labeling studies. These experiments will 





well as give insight into other proteins that the probe might label. Together, these results 
demonstrate that an alkyne based nanoprobe can be utilized to create multifunctional 
probes for receptor targeting.      
 
Figure 4.3. Fluorescent imaging of ketamine nanoprobe SM-V-127 pre-agonist 
addition. 
 







 The alkyne based nanoprobe described in this work shows that the scaffold can be 
utilized to rapidly synthesize multifunctional probes to target receptors of interest. The 
addition of a ketamine ligand through a click reaction with the alkyne nanoprobe allowed 
for visualization of NMDA receptors in transfected CHO cells. The alkyne nanoprobe 
can provide a general labeling tool available for scientists to study various membrane 
bound endogenous receptors. 
4.5 Materials and Methods 
4.5.1 General information 
All reagents, biological and chemical, were purchased through Fisher Scientific 
(Fair Lawn, NJ, USA).  All reactions involving air- and moisture-sensitive reagents were 
performed under an argon atmosphere using syringe-septum cap techniques.  DMF and 
CH2Cl2 were dried by storing over molecular sieves (4Å).  Analytical thin-layer 
chromatography (TLC) was carried out using Merck Silica gel 60 F254 aluminum sheets.  
Compounds were detected as single spots on TLC plates and visualized using UV light 
(254 or 366 nm) or ninhydrin.  Merck silica gel (35–70 mesh) was used for flash 
chromatography.  
1
H NMR spectra were recorded on a 500 MHz Bruker NMR 
spectrometer using the residual proton resonance of the solvent as the standard.  
Chemical shifts are reported in parts per million (ppm).  When peak multiplicities are 
given, the following abbreviations are used: s, singlet; bs, broad singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet.  
13
C NMR spectra were proton decoupled and recorded on 





standard.  Mass spectra were measured either on a Waters ZQ device for LRMS and at 
the UMass Mass Spectrometry facility for HRMS.   
4.5.2 Synthesis of alkyne nanoprobe 
Synthesis of 2-((1-(4-(6-acrylamidohexanamido)-5-(tert-butoxy)-5-oxopentanoyl)-7-
nitroindolin-4-yl)oxy)acetic acid (2) 
Indoline 1 (0.400 g, 0.662 mmol) was dissolved in MeOH (22 mL) and treated 
with 1 M NaOH (993 μL).  The reaction mixture was stirred at room temperature for 16 
hours then neutralized with 1 M citric acid (993 μL) and concentrated via rotary 
evaporation.  The residue was diluted with H2O (10 mL), acidified to pH 2 with 1 M 
citric acid, and extracted with CH2Cl2 (3 x 20 mL).  The organic layer was dried with 
MgSO4, filtered, and the solvent removed via rotary evaporation to yield 380 mg (97% 
yield) of product.  The product was used without further purification. 
1
H NMR (400 MHz, CD3OD) δ ppm 7.73 (d, J = 9.09 Hz, 1 H) 6.78 (d, J = 9.09 Hz, 1 H) 
6.21 - 6.24 (m, 2 H) 5.64 (dd, J = 8.34, 3.79 Hz, 1 H) 5.51 (s, 1 H) 4.30 - 4.34 (m, 2 H) 
3.24 - 3.29 (m, 2 H) 3.20 (t, J = 7.96 Hz, 2 H) 2.83 (s, 2 H) 2.24 - 2.33 (m, 2 H) 1.53 - 
1.71 (m, 5 H) 1.47 - 1.50 (s, 9 H) 1.38 - 1.45 (m, 3 H) 
Synthesis of tert-butyl 2-(6-acrylamidohexanamido)-5-(7-nitro-4-(2-oxo-2-(prop-2-
yn-1-ylamino)ethoxy)indolin-1-yl)-5-oxopentanoate (3) 
Carboxylic acid 2 (0.600 g, 1.02 mmol) and EDC (0.290 g, 1.53 mmol) were 
dissolved in dry CH2Cl2 (3 mL) under argon and stirred for 10 min.  Propargylamine (196 
μL, 3.06 mmol) dissolved in dry CH2Cl2 (2 mL) was added slowly to the reaction mixture 
and allowed to stir for 16 hours.  The solvent was removed via rotary evaporation and the 





NaHCO3, brine, dried with MgSO4, and the solvent removed to yield 480 mg (75% yield) 
of  a red oil. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.66 (d, J = 9.00 Hz, 1 H), 6.98 (t, J = 5.42 Hz, 1 H), 
6.55 (d, J = 9.00 Hz, 1 H), 6.47 (d, J = 7.63 Hz, 1 H), 5.99 - 6.11 (m, 2 H), 5.52 (dd, J = 
10.22, 1.53 Hz, 1 H), 4.57 (d, J =1.68 Hz, 2 H), 4.41 (ddd, J = 9.12, 7.67, 3.97 Hz, 1 H), 
4.16 (t, J = 8.16 Hz, 2 H), 4.08 (dd, J = 5.26, 2.06 Hz, 2 H), 3.13 (d, J = 2.59 Hz, 1 H), 
3.12 (t, J = 6.56 Hz, 2 H), 2.44 - 2.59 (m, 2 H), 2.11 - 2.25 (m, 4 H), 1.99 - 2.07 (m, 1 H), 
1.98 (s, 1 H), 1.64 (s, 2 H), 1.51 - 1.58 (m, 2 H), 1.40 (s, 9 H), 1.26 (d, J = 7.32 Hz, 2 H), 
1.19 (t, J = 7.17 Hz, 1 H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.46, 171.15, 170.76, 166.87, 165.71, 156.33, 
136.71, 136.05, 131.01, 126.06, 125.47, 123.33, 107.60, 82.33, 79.00, 71.78, 67.72, 
60.41, 52.61, 49.90, 39.03, 35.89, 32.05, 28.86, 26.79, 26.27, 26.04, 24.69, 21.06, 14.20. 
LCMS (ESI-TOF) Calc for C31H41N5O9[M+1] ; 628.69, Found: 628.50 
Synthesis of 2-(6-acrylamidohexanamido)-5-(7-nitro-4-(2-oxo-2-(prop-2-yn-1-
ylamino)ethoxy)indolin-1-yl)-5-oxopentanoic acid (4) 
Alkyne 3 (0.110 mg, 0.175 mmol) was dissolved in a 10% TFA/CH2Cl2 solution 
(2 mL) and stirred for 12 hours at room temperature.  The solvent was removed via rotary 
evaporation to yield 120 mg (98% yield) of a red oil.  The product was used without 
further purification. 
1
H NMR (500 MHz, CD3OD) δ ppm 7.74 (d, J = 9.00 Hz, 1 H), 6.79 (d, J = 9.16 Hz, 1 
H), 6.20 - 6.24 (m, 2 H), 5.64 (dd, J = 9.08, 2.98 Hz, 1 H), 4.73 (s, 2 H), 4.46 (dd, J = 





4 H), 2.64 - 2.75 (m, 2 H), 2.62 (t, J = 2.52 Hz, 1 H), 2.27 - 2.31 (m, 3 H), 2.00 - 2.09 (m, 
3 H), 1.63 - 1.70 (m, 2 H), 1.52 - 1.61 (m, 2 H), 1.36 - 1.44 (m, 2 H). 
13
C NMR (500 MHz, CD3OD) δ ppm 174.96, 173.53, 171.36, 168.43, 166.72, 157.00, 
136.33, 135.79, 130.70, 125.11, 124.67, 124.16, 107.65, 78.92, 70.88, 67.06, 51.78, 
49.98, 38.88, 35.23, 31.50, 28.58, 27.89, 26.09, 25.07. 
LCMS (ESI-TOF) Calc for C27H33N5O9[M+1] ; 572.23, Found: 572.20 
Synthesis of rhodamine-alkyne nanoprobe 5 
Carboxylic acid 4 (24 mg, 0.042 mmol), EDC (12 mg, 0.063 mmol), and HOBt 
(10 mg, 0.063 mmol) were dissolved in dry DMF (1 mL) under argon and stirred for 10 
min.  Rhodamine cadaverine (27 mg, 0.042 mmol) and DIPEA (15 μL, 0.084 mmol) 
were dissolved in dry DMF (1 mL) and added slowly to the reaction mixture.  After 
stirring the reaction for 16 hours, the solvent was removed via rotary evaporation and 
column chromatography was performed utilizing 80:10:10 CH2Cl2:CH3CN:MeOH as 
eluent to yield 26 mg (52% yield) of a deep purple oil.  
1
H NMR (500 MHz, CD3OD) δ ppm 8.66 (s, 1 H) 8.08 - 8.14 (m, 1 H) 7.86 (d, J = 7.17 
Hz, 1 H) 7.68 (d, J = 8.85 Hz, 1 H) 7.44 - 7.54 (m, 2 H) 7.12 (d, J = 9.46 Hz, 2 H) 6.99 
(d, J = 9.46 Hz, 2 H) 6.92 (s, 2 H) 6.75 (d, J = 9.00 Hz, 1 H) 6.15 - 6.24 (m, 2 H) 4.68 (s, 
2 H) 4.33 (d, J = 7.32 Hz, 1 H) 4.26 (t, J = 7.86 Hz, 2 H) 4.03 (s, 2 H) 3.67 (q, J = 6.56 
Hz, 10 H) 3.14 - 3.25 (m, 8 H) 3.02 (t, J = 6.33 Hz, 2 H) 2.61 (d, J = 2.29 Hz, 3 H) 2.27 
(t, J = 7.32 Hz, 3 H) 2.04 - 2.14 (m, 1 H) 1.95 (dd, J = 14.42, 7.10 Hz, 1 H) 1.59 - 1.67 
(m, 3 H) 1.45 - 1.57 (m, 8 H) 1.25 - 1.39 (m, 20 H) 
13
C NMR (500 MHz, CD3OD) δ ppm 174.74, 171.32, 168.28, 167.90, 166.62, 157.90, 





127.92, 126.43, 126.32, 125.08, 124.71, 124.11, 113.87, 113.67, 107.68, 95.64, 79.03, 
78.13, 77.88, 77.62, 70.95, 67.06, 53.02, 50.01, 45.49, 42.68, 38.88, 35.37, 31.56, 29.13, 
28.77, 28.54, 27.96, 27.93, 27.06, 26.17, 25.92, 25.83, 25.04, 11.58 
LCMS (ESI-TOF) Calc for C60H75N9O14S2  [M+1] ; 1210.42, Found: 1210.40 
4.5.3 Synthesis of ketamine nanoprobe (6) 
Rhodamine-alkyne nanoprobe 5 (17 mg, 0.0140 mmol) was combined with CuI 
(1.2 mg, 0.0040 mmol) and sodium ascorbate (1.2 mg, 0.0040 mmol) and dissolved in 
CH3CN/H2O (1 mL/0.1 mL). Ketamine azide ligand 7 (3.0 mg, 0.0094 mmol) dissolved 
in CH3CN (1 mL) was then added and the reaction mixture was allowed to stir for 16 
hours. The solvent was removed via rotary evaporation and the product was purified by 
preparative-HPLC to obtain 8.8 mg (61% yield) of product as a pink solid. (XBridge Prep 
C18 5μm (10 x 100 mm) column: H2O and CH3CN/0.1% formic acid as the mobile 
phase.)  
LCMS (ESI-TOF) Calc for C78H100ClN13O15S2 [M+1] ; 1559.29, Found: 1558.90 
HRMS (ESI-TOF) Calc for C78H100ClN13O15S2 [M+2]
+
; 780.8376, Found: 780.8393 
4.5.4 Synthesis of ketamine azide ligand (7) 
To a suspension of K2CO3 (110 mg, 0.670) in CH3CN (3 mL) was added 2-
amino-2-(2-chlorophenyl)cyclohexanone (50.0 mg, 0.223 mmol) and a catalytic amount 
of KI. 1-azido-6-bromohexane (55.0 mg, 0.268 mmol) dissolved in CH3CN (2 mL) was 
then added dropwise and the solution was heated to reflux and stirred for 16 hours. After 
cooling to room temperature the solvent was removed via rotary evaporation. H2O (10 





organic layers were combined, washed with brine (10 mL), dried with MgSO4, and 
evaporated via rotary evaporation. The crude material was purified by column 
chromatography use 1:1 EtOAc:hexanes as eluent to yield  23 mg (30% yield) as a clear 
oil. 
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CAGED AZIRIDINIUM-PHOTOCONTROL OVER ALKYLATION OF 
NUCLEOPHILES 
 
Adapted with permission from McCarron, S.T.; Feliciano, M.; Johnson, J.N.; Chambers, 
J.J. Photoinitiated release of an aziridinium ion precursor for the temporally controlled 
alkylation of nucleophiles. Bioorganic and Medicinal Chemistry Letters. 2013, 8, 2395-
2398. Copyright 2013 Elsevier Limited. License number 
3618870307317 
5.1 Introduction 
The development of novel and efficient methods aimed at the facile alkylation of 
biological substrates has been a topic of much effort in the field of chemical biology
1,2,3,4
. 
The application of small molecule probes to a biological target allows for subcellular 
imaging and the study of dynamic protein motions in and on cells. The power of these 
molecules can be synergistic with new sub-diffraction resolution microscopy methods, 
which typically rely on the delivery and attachment of fluorophores to proteins of 
interest
5,6,7
. As mentioned in previous chapters, these fluorophores are usually delivered 
by one of two methods: genetic tagging of the protein of interest using a naturally 
fluorescent reporter protein such as GFP or by non-covalent labeling using the tried-and-
true antibody method. However, these methods either require genetic engineering of the 
target protein or non-covalent interactions of fairly large antibodies for highlighting the 





One method for the delivery of a small molecule probes to a protein target is 
through the application of photochemically activated moieties that utilize small molecules 
to target proteins and then covalently modify the protein of interest for downstream 
analysis
8,9,10
. In particular, there are three classes of commonly used photoreactive 
moieties that allow for photo-crosslinking to proteins, which include aryl azides, 
diazirines, and substituted benzophenones. Each of these functional groups is chemically-
inert under dark conditions but can revert to a reactive species by the application of high 
energy, ultraviolet light. Upon photo-activation, azides and diazirine groups produce a 
nitrene-like or a carbene intermediate, respectively, while benzophenones depend on 
radical aryl ketylintermediates for reactivity
11,12
. However, the reactivity of these 
compounds is difficult to tune and often react with the solubilizing media or buffer, 
thereby reducing their labeling efficiency.  
Recently, there has been the development of multifunctional probes that allow for 
traceless labeling of endogenous proteins
13,14,15
. As discussed in Chapters 3 and 4, these 
probes consist of a ligand for binding to the target protein, a fluorophore for visualization, 
and some electrophilic moiety that forms a new covalent bond with the target upon 
binding to the protein. Generally, the native nucleophile is the sulfhydryl of cysteine that 
is intrinsic to the target protein and the small molecule-based electrophile contains a 
maleimide for selective bioconjugation to this residue. While these probes offer many 
advantages in terms of their size and their ability to be ‘traceless’, they all are limited by 
the electrophile delivered to the biological system and electrophiles are known to react 
with off-target nucleophiles
16
. Here, we report the development of a small, 





This chapter will focus on a method to photoinitiate the release of 2-chloro-N,N-
dimethylethylamine; a molecule that is similar in reactivity to the nitrogen mustard 
alkylating agent bis(2-chloroethyl) ethylamine (HN1). This particular compound is 
known to form the promiscuous N,N-dialkylaziridinium electrophile under biologically-
relevant conditions
17,18,19
. In addition, the N,N-dialkylaziridinium ion formed from HN1 
has been implicated in the alkylation of biological nucleophiles, most commonly the 
guanine of DNA after exposure to this nitrogen mustard. We reasoned that the formation 
of N,N-dimethylaziridinium from 2-chloro-N,N-dimethylethylamine can be initiated with 
light if we were to chemically mask the important lone pair of electrons on the tertiary 
amine of the latter in the form of a photoreleasable quaternary amine from molecule 2 
(Scheme 5.1). The photocage we chose to employ is the 4-methyl-7-methoxycoumarin 
chromophore for a number of reasons: (1) this chromophore will undergo heterolytic 
bond cleavage resulting in the release of a tertiary amine in neutral form with the lone 
pair of electrons made available for subsequent ring closure. (2) the coumarin can be 
activated by either ultraviolet light or two-photon infrared light which could allow for 
more precise spatial control of labeling and, (3) the quantum yield of release from this 
chromophore is highly efficient
20
. The N,N-dimethylaziridinium that is formed is 
expected to be relatively long lived in biological conditions. Reports on similar 
aziridinium species suggest that the half-life of the aziridinium in phosphate buffered 









Scheme 5.1. Photo-induced aziridinium formation and subsequent alkylation of the 
pyridine-based nucleophile, NBP. 
 
5.2 Experimental methods 
The caged molecule 2 was synthesized by alkylating N,N-dimethylaminoethanol 
with 4-chloromethyl-7-methoxycoumarin
22
 to form 1 in 72% yield followed by 
substitution of the hydroxyl with chloride using thionyl chloride to afford 2 in 81% yield 
(Scheme 5.2). To explore the photoinitiated release of the 2-chloro-N,N-
dimethylethylamine and the subsequent formation of an aziridinium ion, we employed a 
colorimetric assay to determine nucleophile alkylation. 4-Nitrobenzylpyridine (NBP) has 
been utilized as a detector of alkylation in the literature because N-alkylation and facile 
work-up produces a deep purple color that is easy to quantify using a UV/Vis 
spectrophotometer
23,24
. The pyridinium nitrogen is quarternized by the electrophile and 
under basic work up a benzylic proton is removed, which conjugates the aryl rings to 
produce a deep purple color that can be rapidly measured (Scheme 5.1). We used this 





non-caged 2-chloro-N,N-dimethylethylamine, the caged molecule 2 kept in the dark, and 
of the caged molecule after exposure to a short pulse of 365 nm light from an LED light 
source. In addition, 2-chloro-N,N-dimethylethylamine and caged 2 were incubated with 
four amino acids (cysteine, lysine, serine, and arginine) that are biologically relevant 
nucleophiles at physiological pH and temperature. We chose these amino acids to give 
insight to protein labeling studies that can be done in the future. The 2-chloro-N,N-
dimethylethylamine and caged 2 were allowed to react with each amino acid and the 
reaction was analyzed by LC/MS to determine the extent of labeling. 
 
Scheme 5.2. Synthesis of caged N,N-dimethylaziridinium precursor 2. 
 
5.3 Results and Discussion 
5.3.1 NBP alkylation assay 
Our investigation began with the measurement of aziridinium formation from 2-
chloro-N,N-dimethylethylamine (hydrochloride) in aqueous buffer in the presence of 
NBP at 37˚C and pH 7.4. We decided to perform these reactions at physiological pH and 
temperature due to our future plans to employ this photochemistry on live mammalian 
cells. We followed the time course of NBP alkylation by removing aliquots of the 
reaction mixture and incubating them with stop solution followed by ethyl acetate 
extraction of the colored product (Figure 5.1). The OD535 of the ethyl acetate layer was 





reaction runs. In parallel, we prepared an identical solution of compound 2 and allowed it 
to react with the NBP in the dark. We expected some background reactivity due to SN2 
displacement of the alkyl chloride on the caged molecule by the nucleophilic pyridine. 
However, the caged molecule did not react at a detectable level, suggesting that the 
quarternization of the tertiary amine is sufficient to eliminate much of the electrophilic 
character of this alkyl chloride (Figure 5.2). Upon photoinitiated release of 2-chloro-N,N-
dimethylethylamine from the coumarin cage, NBP alkylation was observed and was quite 
similar in reaction rate to the non-caged 2-chloro-N,N dimethylethylamine. The 
photoinitiated release of 2-chloro-N,N-dimethylethylamine allows the aziridinium 




Figure 5.1. Rate of NBP alkylation. Data points represent average of three independent 
experiments (n=3 for each experiment) of reaction between alkylating molecule and NBP 
following work-up and analysis. Lines are calculated as exponential associations. Green 
circles are for 2-chloro-N,N-dimethylethylamine, black boxes are for caged molecule 2 
maintained in the dark, and purple triangles are for caged molecule 2 (at the same 
concentration and quantity as that used for the green circles) after exposure to 1 min of 







Figure 5.2. Photographs of alkylation reactions post-workup. (a) 2-chloro N,N- 
dimethylethylamine incubated with NBP at 30 min, (b) caged molecule 2 irradiated at 
365 nm for 1 min and incubated with NBP for 30 min, and (c) caged molecule 2 kept in 
the dark with NBP at 30 min. The top, color-containing layer is the ethyl acetate extract 
that is normally analyzed via UV/vis. 
 
 
5.3.2 Mass spectroscopy analysis 
Next, we investigated the selectivity of the photo-initiated release of 2-chloro-
N,N-dimethylethylamine towards four amino acids that represent biologically-relevant 
potential nucleophiles. The N-terminus of the amino acids were Fmoc-protected to 
discourage the alkylation of the free amine versus the side chain functional groups. As a 
positive control, 2-chloro-N,N-dimethylethylamine hydrochloride was incubated with 
Fmoc-serine, lysine, arginine, or cysteine for 2 hours at 37˚C and pH 7.4 in 2.5 mL of 
PBS/DMSO (4:1) solution. After incubation, 50 μL of the reaction mixture was diluted to 
1 mL in methanol and analyzed by LC/MS. Under these conditions only cysteine was 
found to be alkylated by 2-chloro-N,N-dimethylethylamine (MW = 415.2). Likewise, 





conditions in the dark and after irradiation with UV light. After 2 hours of incubation, the 
mass corresponding to the alkylated amino acids were not found for caged 2 with no UV 
irradiation. In addition, the mass corresponding to unreacted caged 2 was present, 
indicating that the cage was not reactive to the buffer at a detectible level. However, 
following exposure to 1 min of 365 nm light, the mass corresponding to the alkylated 
amino acids was only found in the case of cysteine (MW = 415.2). This finding parallels 
the results from the positive control experiment with 2-chloro-N,N-dimethylethylamine. 
5.4 Conclusion 
In summary, we have developed a convenient method for the photoinitiated 
release of the electrophile N,N-dimethylaziridinium from 2-chloro-N,N-
dimethylethylamine in situ. While our data does not conclusively confirm the production 
of the aziridinium moiety, we have shown that our caged molecule is unreactive before 
the release with light. Going forward, we plan to synthesize a similar molecule that 
contains a ligand and a propargyl handle to allow for the electrophilic attachment to a 
protein of interest. This alkyne will allow for a subsequent [3+2] cyclization (click 
reaction) with an azido-based fluorophore or biotin. The present molecular system that is 
the subject of this chapter is chemically-inert when kept in the dark and is stable in PBS 
solution for >30 days at room temperature. The reactive species is only generated after 
light is applied to unmask the tertiary amine. The application of this technology to protein 
labeling studies could offer new tools to spatially limit protein modification for the 
purpose of protein tracking on cells. The technology will also add another versatile tool 






5.5 Material and Methods 
5.5.1 General information 
All reagents were purchased through Fisher Scientific (Fair Lawn, NJ, USA). 
Merck silica gel (35–70 mesh) was used for flash chromatography. NMR spectra were 
recorded on a 400 MHz Bruker NMR spectrometer using the residual proton resonance of 
the solvent as the standard for proton spectra and the carbon signal of the deuterated 
solved as the internal standard for carbon spectra. Chemical shifts are reported in parts 
per million (ppm). When peak multiplicities are given, the following abbreviations are 
used: s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Mass 
spectra were measured on a Waters ZQ device for LRMS while HRMS data was 
collected at the University of Massachusetts Mass Facility which is supported, in part, by 
the National Science Foundation. The colorimetric absorption measurements were made 
on an Evolution 100 UV/Vis spectrometer. 
5.5.2 Synthesis of caged electrophile 
Synthesis of 2-Hydroxy-N-((7-methoxy-2-oxo-2Hchromen-4-yl)methyl)-N,N-
dimethylethanaminium (1) 
To a stirred solution of 4-chloromethyl-7-methoxycoumarin (500 mg, 2.23 
mmol), prepared according to a previous report
22
 in methanol (15 mL) was added N,N-
dimethylethanolamine (896 μL, 8.92 mmol). The reaction mixture was heated to reflux 
and allowed to stir for 24 hours. The reaction mixture was cooled to room temperature 
and the solvent was removed via rotary evaporation. The crude product was dissolved in 





(72% yield) of a white solid precipitated. The solid was collected by filtration and was 
rinsed with hexanes and used without further purification. 
1
H NMR (400 MHz, D2O) δ ppm = 7.78 (ds, J = 9.09, 2.53 Hz, 1H) 6.99 (dd J = 9.09, 
2.53 Hz, 1H) 6.95 (d, J = 2.53 Hz, 1H) 6.58 (s, 1H) 4.73–4.76 (m, 2H) 4.03–4.09 (m, 2H) 
3.83 (s, 3H) 3.59–3.64 (m, 2H) 3.13 (s, 6H). 
13
C NMR (400 MHz, D2O) δ = 163.32, 162.62, 155.31, 142.70, 126.19, 119.26, 113.48, 
112.22, 101.64, 67.30, 62.53, 56.03, 55.49, 51.46. 
HRMS (FAB+) Calcd for C15H20NO4 [M+]: 278.1387. Found: 278.1389. 
Synthesis of 2-chloro-N-((7-methoxy-2-oxo-2H-chromen-4-yl)methyl)-N,N-
dimethylethanaminium (2) 
To the previously-produced alcohol 1 (100 mg, 0.319 mmol) was added thionyl 
chloride (2.0 mL, 28 mmol) and the solution stirred at room temperature for 16 hours. 
The volatiles were removed via rotary evaporation followed by high vacuum to leave a 
white solid that was recrystallized from isopropanol to yield  86 mg (81% yield) of a 
white solid. 
1
H NMR (400 MHz, D2O) δ ppm = 7.79 (d, J = 8.59 Hz, 1H) 6.97–7.05 (m, 2H) 6.58 (s, 
1H) 4.76 (s, 2H) 4.00–4.07 (m, 2 H) 3.86–3.92 (m, 2H) 3.84 (s, 3H) 3.17 (s, 6H). 
13
C NMR (400 MHz, D2O) δ = 163.39, 162.47, 155.31, 142.26, 126.10, 119.36, 113.52, 
112.10, 101.68, 66.18, 62.58, 56.05, 51.23, 35.38. 
HRMS (FAB+) Calcd for C15H19ClNO3 [M+]: 296.1048. Found: 296.1059. 
5.5.3 Photolysis and NBP alkylation assay conditions 
All solutions were kept in the dark (aluminum foil wrapped) except during UV 





2 were prepared by dissolving the hydrochloride salt of 2-chloro-N,N-
dimethylethylamine or the chloride salt of 2 in PBS buffer to a final concentration of 25 
mM. Nitrobenzylpyridine solution was prepared in dry acetone to a final concentration of 
25 mM. Alkylation assays were performed by mixing 1.0 mL of PBS, 500 μL of test 
solution containing either 2 or 2-chloro-N,N-dimethylethylamine, and 500 μL of NBP 
solution and allowing them to incubate at 37˚C. Aliquots of the reaction mixture (100 μL) 
were removed at various times and were immediately quenched by the addition of 400 μL 
ethyl acetate, 500 μL of water, and 63 μL of 1.0 M aqueous KOH. Mixtures were 
vortexed for 1 minute and centrifuged to efficiently separate the layers. The organic layer 
was removed via pipette and was either directly analyzed by UV absorption or, if highly 
colored, diluted 10x or 100x in order to produce OD535 measurements between 0.0 and 
1.0 AU. Each sample was measured after zeroing the UV/Vis detector to pure ethyl 
acetate and each data point was measured in triplicate. Each data point used in the time 
course plot is defined by three separate reactions, aliquot removal, and workup. 
Photolysis of the protecting group was accomplished by irradiating the sample from the 
top of an open 1 dram vial with the light from a LedEngin High Power LED 365 nm 
source (Mouser Electronics, Mansfield, TX, USA) situated 5 mm from the top of the vial 
driven by 600 mA of current.  
5.5.4 Mass spectrometry analysis of amino acid labeling assay 
Stock solutions of the corresponding Fmoc-protected amino acids (Lys, Ser, Cys, 
Arg) were dissolved in DMSO to a final concentration of 14 mM. Control experiments 
were conducted by dissolving the hydrochloride salt of 2-chloro-N,N-dimethylethylamine 





DMSO solution for a final concentration of 28 and 2.8 mM, respectively. Each reaction 
was conducted at pH 7.4 and 37˚C for 2 hours at which time a 50 μL aliquot was 
removed, diluted to 1 mL in methanol, and analyzed by mass spectrometry. In similar 
fashion, caged 2 was dissolved in 200 μL of PBS followed by the addition of 50 μL of 
each amino acid DMSO solution and allowed to react for 2 hours at 37˚C and pH 7.4 in 
the dark. The reaction mixture was then analyzed as previously described. Lastly, for the 
photolysis experiment, caged 2 was dissolved in 200 μL of PBS followed by the addition 
of 50 μL of each amino acid DMSO solution and warmed to 37˚C. The sample was 
irradiated for 1 min from a LedEngin High Power LED 365 nm source and then allowed 
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6.1 Nanoprobe development 
 The alkyne nanoprobe discussed in Chapter 4 provides a method for facile 
synthesis of a multifunctional probe that could be targeted to a variety of receptors. To 
explore the modular nature of this probe further, several portions of the probe can be 
altered to develop a kit for fluorescent labeling of endogenous proteins. In this chapter 
there will be a discussion of the synthesis of a new ligand for targeting NMDA receptors, 
new fluorophore combinations with the probe, and an exploration of linker length for the 
acrylamide electrophile.   
6.1.1 Ifenprodil-based NMDA receptor targeting 
 We have previously developed an azido-analogue of ketamine for 
functionalization of the alkyne nanoprobe, which would give specificity for postsynaptic 
NMDA receptors. Another pharmacophore that targets a subclass of NMDA receptors is 
the drug ifenprodil. Ifenprodil is a lead compound for a major class of antagonists of the 
NMDA receptor with marked selectivity for the NR2B unit. To date, there have been 
several studies to characterize its subtype-specific binding to NMDA receptors both in 
vitro and in vivo
1,2,3,4
. The NR2B containing NMDA receptors are particularly interesting 
to study because they are preferentially enriched in extrasynaptic sites and may 
participate in processes linked to glutamatergic overstimulation, which can cause 
excitotoxicity
5
. Therefore, NR2B-selective antagonists are quite attractive for the 







 Ifenprodil contains two asymmetric centers that give rise to two diastereoisomeric 
forms, threo (R*R*) and the erythro (R*S*) forms seen in Figure 6.1. The threo racemate 
was found to be five times more potent neuroprotective agent than the erythro 
diastereomer in an in vitro glutamate neurotoxicity test
2
.  Investigation of the interaction 
of ifenprodil on NMDA receptors places the binding site at the N-terminal domain of the 
NR2B unit. The potency of this compound is due to the key structural elements that 
incorporate a phenolic aromatic ring connected to a second phenyl ring through a linker 
containing a tertiary amine
7,8,9
. The piperazine ring provides a scaffold to hold the two 
aryl rings in an optimum orientation in the binding site, which contain a lipophilic pocket 









 Work done by Marachand et al. utilized ifenprodil as a ligand for the development 
of small molecule fluorescent probes to characterize the microenvironment of the binding 
site at the NMDA receptor (Figure 6.1)
10
. The authors determined that chemical 
modification of the benzylic hydroxyl moiety for the attachment of linkers is preferable 





hydroxyl with a glutamine residue from NR2B. In addition, a linker bearing a secondary 
amine or amide functional group was necessary to maintain affinity for the NMDA 
receptor
11
. Using this information, we have designed two azido-containing analogues of 
ifenprodil to react with the alkyne nanoprobe to create a multifunctional probe that will 
target NMDA receptors containing the NR2B subunit.  
 The first azido-analogue compound 4 can be synthesized in two steps starting 
from compound 1, which was provided by Dr. Doug Johnson at Pfizer Neuroscience 
(Cambridge, MA). Compound 1 was converted to the azido compound 3 according to a 
stereospecific mesylation/amination sequence through the use of 6-azidohexan-1-amine 
(2), which was synthesized from the corresponding 1,6-diazidohexane. This 
transformation occurs with a retention of configuration as a result of a mechanism with 
anchimeric assistance due to the in situ formation of an aziridinium intermediate
10
. 
Acidic deprotection of the benzyl protected phenol is expected to yield the azido-
analogue 4 (Scheme 6.1).   
 
 






 The second azido-analogue compound 7 can be synthesized in three steps starting 
from compound 1. Under similar reaction conditions used previously, compound 1 will 
be reacted with mono-Boc protected hexyldiamine to produce intermediate 5. Acid 
deprotection of compound 5 is expected to yield amine compound 6, which can react 
with 6-azidohexanoic acid under standard peptide coupling conditions to obtain the 
azido-analogue 7 (Scheme 6.2).  
 
 
Scheme 6.2. Synthesis of ifenprodil azido-analogue 7. 
 Using the rhodamine linked alkyne nanoprobe synthesized previously, we could 
develop two NMDA receptor probes specific for the NR2B subunit by utilizing click 
chemistry with azido-analogues 4 and 7 (Scheme 6.3). Although the pharmacophore is 
the same in both cases, the linker length is varied by 6 carbons. This would allow us to 
determine the effects of linker length on binding affinity and provide insight into which 






Scheme 6.3. Synthesis of ifenprodil based nanoprobes for the NMDA receptor 
6.1.2 Fluorophore modification 
 Another site on the alkyne nanoprobe scaffold for potential modification is the 
addition of different fluorophores to allow for visualization of receptors with different 
colors or photochemical properties. Changing the fluorophore will allow for pulse-chase 
experiments, single molecule imaging, and if the fluorophore is pH or otherwise 
environmentally sensitive, can provide information about the surrounding environment. 
There are a multitude of commercially available fluorophores that are amine-terminated, 
or are easily modified with an amine linker. Of these available fluorophores, several have 
been used to visualize receptors of interest both in vitro and in vivo
12,13,14
. We can 
synthesize several fluorescent nanoprobes starting from the alkyne nanoprobe scaffold 
through peptide coupling with a fluorophore with an amine linker (Figure 6.2). This will 
allow for a fluorescent library of these compounds that can easily be modified with a 






Figure 6.2. Fluorescent analogues for conjugation to the alkyne nanoprobe 
6.1.3 Electrophile linker length  
 An area of chemical space on the nanoprobe scaffold that has not been evaluated 
is the length of the linker containing the acrylamide electrophile. Previously, we have 
discussed the effect on changing the pharmacophore for targeting different receptors of 
interest or changing the fluorophore used to visualize the receptor. The linker length 
between the pharmacophore and the alkyne scaffold is important because it will affect the 
binding affinity of the probe for the receptor being studied. However, the linker length for 
the electrophile also needs to be considered in case there are no endogenous nucleophiles 
in the chemical space of the linker with six carbons. The alkyne nanoprobe scaffold can 
be redesigned to contain an electrophile with a short 3 carbon linker derived from 3-
aminopropanoic acid or a much longer 12 carbon linker derived from 12-
aminododecanoic acid (Figure 6.3). Varying the linker length of the electrophile, coupled 





alkyne nanoprobes that can be applied to various receptors of interest. If there was a 
situation where the pharmacophore used did not lead to labeling of the receptor, now 
there will be more options to optimize conditions for binding and crosslinking of the 
probe.   
 
Figure 6.3. Linker length modification of alkyne nanoprobe 
 
6.2  Caged alkyne electrophile development 
 The caged aziridinium compound discussed in Chapter 5 allowed for control of 
the alkylation of nucleophiles using UV light. Although the aziridinium compound that 
was generated could be visualized using a colormetric assay, it would be difficult to 
monitor electrophilic addition to a protein of interest. Going forward, we will synthesize 
a similar caged compound as discussed before; however, this new molecule will contain 
an alkyne handle for click reactions with a fluorophore or biotin-azide. This new 
molecule can be used for protein labeling and could possibly be used as a new core for 
future iterations of the nanoprobe technology. In essence, this new labeling technology 





  The synthesis of the caged alkyne electrophile 11 can be completed in 3 steps 
from 2-(methylamino)ethanol. 2-(methylamino)ethanol will be alkylated with propargyl 
bromide to yield compound 8. Compound 8 will be used in a reaction with thionyl 
chloride to form the control alkyne-chloro compound 9, as well as to alkylate 4-
chloromethyl-7-methoxycoumarin under reflux conditions to yield caged compound 10. 
The synthesis of caged compound 11 is then completed following the reaction of caged 
compound 10 with thionyl chloride to form the alkyl chloride compound 11 (Scheme 
6.4).  
 
Scheme 6.4. Synthesis of a caged alkyne nitrogen mustard 
 
 To determine whether the addition of the propargyl handle will have an effect on 
aziridinium formation, compound 9 was tested in a NBP alkylation assay to determine if 
it will act similarly to the 2-chloro-N,N-dimethylethylamine control compound from the 
previous study. As shown in Figure 6.4, the alkyne electrophile was able to alkylate NBP, 
which show similar results as the 2-chloro-N,N-dimethylethylamine compound used 
before
15
. In addition, compound 8 was unable to alkylate NBP because it contains an 
alcohol moiety instead of an alkyl chloride like the other two compound tested. This 
suggests that compound 9 is still able to form an aziridinium intermediate and may 





with both compound 9 and caged compound 11 should determine if this technology can 
be utilized to spatially limit protein modification for the purpose of protein tracking on 
cells.     
 
 
Figure 6.4. NBP alkylation assay for alkyne mustard. Left) 2-chloro-N,N-
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Table 7.1 List of abbreviations  
1-ethyl-3-(3-dimethylamino EDC N,N-Diisopropylethylamine DIPEA 
propyl)carbodiimide   
  N,N-Dimethylformamide DMF 
1,3-di(2-toyl)guanidine DTG 
  N-methyl-D-aspartate NMDA 
4-nitrobenzylpyridine NBP 
  Nitrobenzodiazole NBD 
Acetonitrile CH3CN 
  Photoaffinity labeling PAL  
Amyloid lateral sclerosis ALS 
  Potassium carbonate K2CO3  
α-amino-3-hydroxy-5-methyl AMPA 
4-isoxazolepropioic acid  Potassium iodide KI 
 
Chinese hamster ovaries CHO Potassium tert-butoxide KOTBu 
 
Central nervous system CNS Serotonin transporter SERT 
 
Dichloromethane CH2Cl2 Sodium azide NaN3 
 
Dimethyl sulfoxide DMSO Sodium bicarbonate NaHCO3 
 
Dopamine transporter DAT Sodium hydroxide NaOH 
 
Endoplasmic reticulum ER Sodium nitrite NaNO2 
 
Ethanol EtOH Thin layer chromatography TLC 
 
Ethyl acetate EtoAc Thionyl chloride SOCl2 
 
Hydrochloric acid HCl Tin (II) chloride SnCl2 
 
Hydroxybenzotriazole HOBt Triethylamine Et3N 
 
Magnesium sulfate MgSO4 Trifluoroacetic acid TFA 
 








7.1 Mass spectroscopy data 




LC-MS data for SERT nanoprobe (SM-V-37) 
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